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Abstract 
This pilot study validated two psychometric scales, the Psychosocial 
Adjustment to Hereditary Disease (PAHD) and the Hereditary Diseases and Genetic 
Testing (HD-GT) scales, for use in the Newfoundland and Labrador Arrhythmogenic 
Right Ventricular Cardiomyopathy population. Both scales were previously 
validated in the Newfoundland hereditary non-polyposis colorectal cancer (HNPCC) 
population.  
The target population for this study was individuals born at an a priori 50% 
risk for the TMEM43 mutation that causes ARVC who had undergone genetic testing.  
In total, 73 participants returned completed surveys. 
Psychometric testing of both scales followed the procedures outlined by 
Ware and Gandek (1998) and demonstrated satisfactory data quality, reliability and 
validity. Results indicated potential usefulness in the ARVC population warranting 
analysis with a larger sample size.  
No large-scale differences were found between carriers and non-carriers; 
however, small differences in particular aspects of psychosocial adjustment based 
on gender, gender of transmitting parent, and age were found. 
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CHAPTER 1 
 
 
Introduction 
 
In the early 1990s, the human genome project created opportunities for 
genetic testing for a wide range of hereditary conditions (Rew, 2010). Prior to the 
advent of genetic testing, an individual could not be diagnosed definitively with a 
hereditary condition until he or she began to manifest symptoms. Once symptoms 
appeared, one could undergo clinical testing, but for some hereditary conditions this 
process was ineffective as the opportunity for treatment had passed. For example, a 
person with a hereditary cancer syndrome might only become aware of the 
condition once a late stage tumor was found.  
As the field of genomic science evolved, so too did the availability of 
predictive genetic testing for hereditary conditions (Erskine et al., 2014; Manuel & 
Brunger, 2014; Smart et al., 1996) . These tests, which can be conducted from a 
small blood or tissue sample, can provide valuable health information for 
individuals and families, identify pre-symptomatic individuals, and sometimes 
improve medical management of the condition (Erskine et al., 2014; Lodder & 
Bezzina, 2013; Murray, 2012) . Pre-symptomatic or predictive genetic testing does 
not change the disease course but it allows for a definitive diagnosis prior to the 
onset of symptoms, when treatment may be more effective. 
While there are many potential benefits associated with genetic testing, it is a 
technology with the potential to cause psychological harm (Rew, 2010). Hereditary 
conditions are unique in that the individual may be burdened not only by the 
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condition itself but also by transmission implications (Aatre & Day, 2011) . Families 
can endure years of speculation, assumptions, and uncertainties associated with the 
family illness. Within the context of family relationships, the process of predictive 
genetic testing can be very complex (Ormondroyd, Oates, Parker, Blair, & Watkins, 
2014) .  
Reasons for seeking or refusing genetic testing are highly variable but certain 
themes are consistent across the literature. The most common motivator is the need 
to define one’s own risk to protect one’s own health and/or the health of children 
(Aatre & Day, 2011; Erskine et al., 2014; Ormondroyd et al., 2014) . Other common 
motivators include needing an explanation for a family member’s death, needing a 
definitive diagnosis, guiding medical management, taking control of the future, or 
pressure from family members or clinicians (Claes, Denayer, Evers-Kiebooms, 
Boogaerts, & Legius, 2004; Clark et al., 2000; Erskine et al., 2014; Esplen et al., 2007; 
Satia, McRitchie, Kupper, & Halbert, 2006) .  Common reasons for refusing genetic 
testing include concerns about the effect of the results on other family members, 
fear of results, misconceptions or lack of knowledge surrounding risk, and not fully 
understanding the advantages of testing (Erskine et al., 2014).  
Many reasons people have to seek or refuse genetic testing are common 
across a wide range of hereditary conditions. This is likely due to the fact that 
decisions surrounding genetic testing are made within the context of the family and 
are not necessarily autonomous. While the literature is lacking in the psychosocial 
impact of inherited heart conditions, and specifically arrhythmogenic right 
ventricular cardiomyopathy (ARVC), many of the themes that emerge from 
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inherited cardiac conditions and inherited cancer studies are related to the effects of 
genetic testing on the family as a whole. Some of the best-studied hereditary 
conditions follow an autosomal dominant pattern, meaning that an individual need 
inherit the defective gene from just one parent to be affected, versus autosomal 
recessive in which an affected individual inherits the defective gene from both 
parents. As ARVC follows an autosomal dominant pattern, it is plausible that many 
of these concepts will be relevant for families affected by ARVC as well.  
The idea that decisions about hereditary conditions are made within a social 
context rather than in isolation may help explain conflicting results in psychosocial 
studies. While positive genetic test results provide individuals with a sense of 
closure and control leading to better psychosocial well being, they may also disrupt 
family relationships and lead to feelings of guilt and anger (Djurdjinovic, 1998; 
Duncan et al., 2008; Erskine et al., 2014). Similarly, individuals who test negative 
may be relieved while other individuals may experience a form of survivor’s guilt 
(d'Agincourt-Canning, 2006; Schwartz et al., 2002).  In order to properly anticipate 
and manage the various psychosocial impacts associated with genetic conditions, 
clinicians and counsellors must understand the social context in which an 
individual’s attitudes are embedded.  
There is a conspicuous lack of research specifically focused on the 
psychosocial impacts of inherited cardiac conditions. With the exception of studies 
focused on the psychosocial impact of implantable cardioverter defibrillators (ICDs), 
no research has quantitatively explored the psychosocial burden of living with ARVC.  
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The purpose of this study is to validate two psychosocial survey tools, 
originally created for use with families affected by hereditary non-polyposis 
colorectal cancer (also known as HNPCC or Lynch syndrome (LS)), which is also an 
autosomal dominant condition. The tools are: 1. the Psychosocial Adjustment to 
Hereditary Disease (PAHD) Scale, and 2. the Hereditary Diseases and Genetic 
Testing (HD-GT) Scale (Watkins et al., 2013; Way et al., 2011) . The purpose is to 
explore whether these tools are valid for use in the Newfoundland ARVC population, 
as well as to provide support for the results of preliminary qualitative research with 
ARVC families in the province (Etchegary, Pullman, Simmonds, Young, & 
Hodgkinson, 2014; Manuel & Brunger, 2014)  . If the tools prove to be valid it will 
allow the use of quantitative scores to determine which, if any, social or clinical 
factors are related to the psychosocial impact on individuals at risk for ARVC.    
 
Background and Rationale 
 
ARVC is an autosomal dominant condition characterized by fibrofatty 
infiltration of the myocardium, resulting in life-threatening arrhythmias that may 
lead to sudden cardiac death (SCD) or biventricular heart failure (K. A. Hodgkinson 
et al., 2013) . There are currently 11 genes known to be associated with ARVC, each 
with its own penetrance, expressivity, and disease progression.  The subgroup of 
ARVC being studied here is a particularly lethal genetic subtype of ARVC caused by a 
missense mutation (which changes the amino acid serine to the amino acid leucine: 
p.S358L) in transmembrane protein 43 (TMEM43) (Christensen, Andersen, 
Tybjaerg-Hansen, Haunso, & Svendsen, 2011; Merner et al., 2008; Te Riele, Tandri, & 
Bluemke, 2014) . While other subtypes of ARVC demonstrate reduced penetrance 
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and variable expressivity, this subtype is distinct in that it is fully penetrant and 
often lethal in young adults (Merner et al., 2008).  The median age of death is 41 
years in men and 71 years in women, while the median age at which the condition 
reaches 100% penetrance is 63 years in men and 76 years in women (Merner et al., 
2008). The prevalence of ARVC is estimated to be between 1 in 1000 to 1 in 5000 in 
the general population; however, due to the founder effect of the island population 
in the province, the prevalence of ARVC in Newfoundland and Labrador is estimated 
to be between 1 in 1000 and 1 in 500 (Etchegary et al., 2014; Sen-Chowdhry, Syrris, 
& McKenna, 2005) . With 24 families known (at the time of writing, and where 
'family' can reflect between 500 to 1000 persons in the family tree) to have a history 
of this particularly lethal subtype, the unusually high prevalence makes ARVC a 
priority for genetics research in the province.  
 
ARVC and Genetic Testing 
 
Prior to 1998, genetic testing was not available for ARVC (Hodgkinson et al., 
2009; Manuel & Brunger, 2014) . Diagnosis was based on family history and clinical 
manifestations including, but not limited to, ventricular tachycardia, heart failure, or 
SCD; this method of diagnosis had a sensitivity of less than 20% (K. A. Hodgkinson et 
al., 2013; Manuel & Brunger, 2014; McKenna et al., 1994) .  
As the field of genomics moved forward, this particular subtype of ARVC was 
linked to the locus 3p25, which allowed clinicians to determine whether a person 
was high-risk or low-risk via haplotype analysis (Ahmad et al., 1998). Though there 
remained a theoretical error with this process and it was not possible to completely 
rule out the possibility of ARVC, a nearly definitive positive diagnosis could be made 
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(Hodgkinson et al., 2009) . It was later found that the causative gene was present in 
100% of those who tested positive for the associated haplotype, therefore 
confirming the accuracy of haplotype analysis (Hodgkinson et al., 2009)  
Direct mutation testing became possible in 2007 with the discovery of the 
causative gene for this subtype of ARVC (Merner et al., 2008). Merner et al. (2008) 
found a missense mutation (p.S358L) in TMEM43, which was present in all 
symptomatic individuals as well as 28.8% of non-symptomatic individuals. This 
discovery opened the door for direct mutation analysis using DNA extracted from 
peripheral lymphocytes (K. A. Hodgkinson et al., 2013) .  
Probands, the first individuals in a family diagnosed with an inherited 
condition, were identified when they presented with symptoms that fit the ARVC 
diagnostic criteria. Pedigrees were then built from a proband’s family history to 
identify other at-risk relatives. Prior to the advent of genetic testing, this was the 
only way to determine if an asymptomatic individual was at risk for the condition. 
Today, individuals identified through the pedigree as being at risk have genetic 
testing available to them for confirmation. When an affected person is identified, 
implantation of an ICD may significantly improve life expectancy by increasing the 
chance of survival during potentially fatal arrhythmias (K. A. Hodgkinson et al., 
2005) . Since this subtype of ARVC is fully penetrant, a positive gene test indicates 
that an individual will eventually show symptoms; however, expressivity is varied, 
particularly in women. Family history may also influence an individual’s decision 
about when to have children tested for the gene, based on the estimated age of onset 
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of symptoms. Though the genetic test itself is conclusive, variable expressivity adds 
an element of uncertainty as the exact symptoms and age of onset can vary. 
 
Psychosocial Implications of Genetic Testing  
 
  
 Research on the psychosocial impact of hereditary disease has been 
conflicting, especially in terms of the outcomes of genetic testing. However, virtually 
all authors attribute these differences at least partially to social dynamics. 
Regardless of how an individual reacts to test results initially, it has been shown that 
the availability of social support is associated with better psychosocial adjustment 
over time, an effect that is more pronounced in carriers than non-carriers (Lapointe 
et al., 2013).  
As with any inherited condition, ARVC is embedded in family context. 
Differing attitudes toward genetic testing have the potential to strain relationships, 
but conversely, making use of a family support network can bring those dealing with 
ARVC closer together. Active sharing is a key factor in maintaining close 
relationships and building social support; therefore, open discussions about genetic 
information can serve to strengthen family relationships (Lapointe et al., 2013).  
For those with weak family relationships, it may be difficult to have open 
discussions about hereditary disease. The duty to be tested is a consistent theme in 
genetics research, especially in conditions such as ARVC, where ameliorative 
treatment is available or children are involved (Aatre & Day, 2011; Erskine et al., 
2014; Etchegary et al., 2014; Hodgkinson & Pullman, 2010; Manuel & Brunger, 
2014; Pullman & Hodgkinson, 2006) . Due to the nature of hereditary conditions, a 
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positive test result has implications for the family as a whole. One family member’s 
result has the potential to inadvertently reveal the genetic status of other family 
members who may have not agreed to testing or could raise issues of adoption or 
paternity that had not yet been previously discussed (Aatre & Day, 2011) . For close 
families, the decision to go through with testing and coping with the outcomes is a 
collaborative process, but for those families with already strained relationships, one 
family member challenging the autonomy of another serves only to strain those 
relationships further (Aatre & Day, 2011; Manuel & Brunger, 2014) .  
This study represents the first attempt to quantify the level of psychosocial 
adjustment for individuals at risk for ARVC and to identify potential areas for 
concern. It is critical for clinicians and genetic counsellors to understand how 
decisions are made and how family dynamics benefit or harm an individual in order 
to improve the process of testing and ongoing care. This study may also provide 
some insight into similarities and differences among various inherited conditions. 
Problem Statement 
 
Qualitative studies conducted by the research team as part of a larger project 
found a number of similarities between ARVC and other inherited conditions in 
terms of attitudes toward genetic testing and psychosocial adjustment to risk 
(Etchegary et al., 2014; Manuel & Brunger, 2014) .  Consistent with the literature, 
those at risk for ARVC are driven to genetic testing mainly due to a strong family 
history of the illness, the availability of a reliable predictive test, and a sense of 
relational responsibility (Manuel & Brunger, 2014) . Also consistent with the 
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literature, psychosocial adjustment to ARVC risk is highly dependent on the strength 
of an individual’s social support network.  
 Due to the similarities between ARVC and other inherited conditions, it is 
plausible that two psychometric survey tools developed for use in LS families may 
also be valid in the ARVC population. Two survey tools, the PAHD scale and the HD-
GT scale, were modified for use in this study. Using the final validated version of the 
survey for LS, several items were reworded such that all survey items were 
applicable to ARVC families. The information generated by this pilot study will 
provide insight into the similarities and differences between the psychosocial 
impacts of two different hereditary conditions by examining the reliability and 
validity of the two survey tools. It will also identify potential clinical factors, if any, 
that significantly influence an individual’s score and consequently provide direction 
for future research and clinical practice in the field of genetic counselling. 
 
Purpose and Research Questions 
 
The primary objective of this study is to validate two psychometric survey 
tools, the PAHD scale and the HD-GT scale, for use in the Newfoundland ARVC 
population. The secondary objective is to identify which, if any, clinical factors have 
an influence on the overall score for individuals at risk for ARVC. 
This pilot study aims to address the following questions: 
1. Are the subscales reliable for both tools? 
2. Are the subscales valid for both tools? 
3. Are overall scores correlated with any particular clinical variables? 
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The following chapters outline the literature surrounding the psychosocial 
issues surrounding the genetic process, the psychometric testing of both scales in 
the Newfoundland ARVC population, and significant differences in subscale scores 
in terms of age, sex, sex of the transmitting parent, and mutation status.  
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CHAPTER 2  
 
Literature Review 
 
The purpose of this literature review is to examine the current evidence on 
the factors that influence an individual’s decision to undergo genetic testing and the 
resulting impact of testing on the individual and his or her family. This chapter 
examines the psychosocial issues surrounding the genetic testing process beginning 
with the first knowledge of a familial link, through to the long-term impact of testing 
results. The first section explores how individuals and families make decisions 
about genetic testing which includes perception of risk, as well as factors that 
motivate individuals to seek or forego genetic testing. The second section examines 
the reaction to test results, short-term and long-term psychosocial adjustment, and 
communication of results to others.  
Family Context 
Any illness has an associated psychosocial burden, but inherited diseases 
bring unique anxieties related to risk to other family members and transmission to 
children and grandchildren (Aatre & Day, 2011) . Being at risk for a hereditary 
condition implies risk for first-degree relatives which can elicit feelings of guilt, fear, 
anger, denial, grief, or despair (Djurdjinovic, 1998). The decision to undergo genetic 
testing for a hereditary condition does not occur in a vacuum; the decision cannot be 
truly autonomous due to the implications for other family members (Etchegary et al., 
2014; Manuel & Brunger, 2014) . The complexity of family dynamics may make the 
conversation about disease risk more difficult for certain individuals, especially 
when family members have differing perceptions of risk or viewpoints of genetic 
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testing (Ormondroyd et al., 2014). For example, genetic testing for a hereditary 
condition has the potential to reveal a previously undisclosed adoption, the 
paternity of a child, or implicate first-degree relatives (Aatre & Day, 2011) . 
Risk Perception 
 Perception of risk weighs heavily on motivation to seek or forego genetic 
testing for a hereditary disease. One study showed that low personal risk perception 
is a key factor in choosing not to test (Erskine et al., 2014; Ormondroyd et al., 2014) 
and similarly, qualitative data show that an increase in risk perception, for oneself 
or for a child, often results in seeking testing (Manuel & Brunger, 2014) . In some 
families, misconceptions and uncertainties allow individuals to justify to themselves 
that their risk is lower than it really is. In these families, direct contact with 
clinicians drastically increases uptake of testing as clinicians are able to clarify and 
correct misunderstandings and misconceptions and have a sense of authority that 
other family members do not (Ormondroyd et al., 2014). 
 A qualitative study by Manuel and Brunger (2014) examined the 
relationships between genetic testing uptake and risk perception in the 
Newfoundland ARVC population. One important result of that study was that genetic 
testing uptake was directly related to the progress made by genetic science, 
implying that risk perception is highly dependent on the availability of scientific 
knowledge (accuracy of testing, availability of treatment options, understanding of 
the disease itself). Those who participated in clinical testing prior to the availability 
of any genetic testing knew they were at risk for something but awareness of the 
condition did not translate into an increase in risk perception. When these 
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individuals were provided with the option of haplotype testing in 1998, there was 
no prolonged decision making process. However these individuals had already 
spent significant time contemplating the origins of the condition so that when 
testing became available, it was viewed as the next step in deciphering the condition 
and they were ready to know and prepared to take on this additional knowledge. 
The same increase in testing uptake was seen in 2007 with the introduction of direct 
mutation testing. In both instances, patients were offered immediate, definitive 
testing with increased accuracy.  
 Another significant result of this study was that the presence of symptoms 
significantly increased the chance that an individual underwent testing. The 
decision was especially difficult for those who did not exhibit any of the typical risk 
factors for heart disease; i.e., those who felt healthy, were physically active, and had 
a healthy diet. Similarly, women put much more thought into their decision due to 
the fact that women tend not to be as severely affected. Noted was a sudden 
increase in the number of women being tested in the 1990s when many of the 
women who initially underwent clinical testing in the 1980s began showing early 
symptoms of ARVC. Parents also showed this change in perspective when their 
children began to exhibit symptoms. This may partially be a reflection of some of the 
misconceptions within certain families, as SCD is often the first symptom of this 
particular subtype of ARVC.  
 Also noteworthy, was the lack of urgency from young family members. With 
advances in pre-symptomatic testing and treatment for ARVC, most young people 
had not witnessed as many deaths in the family as did the older generations. Similar 
 25 
to how the onset of symptoms encouraged previously asymptomatic individuals to 
seek testing, having first-hand experience with deaths in the family caused by ARVC 
resulted in a heightened perception of risk.  
 This study demonstrated that scientific evidence and experiential knowledge 
greatly influenced risk perception, which in turn encourages pre-symptomatic 
genetic testing. 
Genetic Testing Decision Making 
The desire to define risk for children and other family members is often cited 
as the primary motivator for genetic testing. Studies of two types of inherited 
cancers, Hereditary Breast and Ovarian Cancer (HBOC) and Lynch syndrome (LS), 
found the desire to provide a risk estimate for children to be the primary motivator 
for seeking out genetic testing (Claes et al., 2004; Clark et al., 2000; Esplen et al., 
2007). Studies of inherited heart conditions report the same result (Aatre & Day, 
2011; Ormondroyd et al., 2014) . Qualitative studies in the Newfoundland ARVC 
population found that at-risk individuals felt a relational responsibility or moral 
duty to children and other first-degree relatives to be tested (Etchegary et al., 2014; 
Manuel & Brunger, 2014) . The desire for closure following the death of one or more 
family members has also been cited as a family-driven motivator to seek genetic 
testing. Those who have lost a child or other family member feel empowered by 
taking preventative measures (Erskine et al., 2014). The family connection can also 
be a factor in deterring people from genetic testing either due to fear that one has 
already passed the gene onto a child or due to the reaction from other family 
members if the gene test is positive (Erskine et al., 2014). 
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Almost as prevalent as the desire to protect the health of family members is 
the desire to protect one’s own health (Claes et al., 2004; Clark et al., 2000; Erskine 
et al., 2014; Esplen et al., 2007; Manuel & Brunger, 2014; Ormondroyd et al., 2014; 
Satia et al., 2006) . ARVC, like many inherited conditions, can be well managed with 
medication and prophylactic surgery so there is a significant benefit to be gained 
through genetic testing (Manuel & Brunger, 2014) . Through early detection and 
early intervention, the life expectancy of individuals with ARVC can be extended 
significantly.  As ARVC symptoms including SCD can appear in individuals under the 
age of 18, it may be beneficial for children to be tested. In most ARVC families, loss is 
part of a child’s life from a very early age and genetic testing can be a natural part of 
the experience (Manuel & Brunger, 2014) . The American College of Medical 
Genetics recommends that minors be tested only if there are clinical implications 
before the age of 18 and if the medical benefits outweigh potential psychological 
harm (Botkin et al., 2015). Male youth with ARVC may be susceptible to SCD starting 
in the late teen years, so it is not uncommon for youth or for parents of at-risk youth 
to choose genetic testing.  
Those who have been diagnosed clinically or those who suspect they may be 
a carrier often seek genetic testing to eliminate uncertainty (Claes et al., 2004; Clark 
et al., 2000; Decruyenaere et al., 1997; Decruyenaere et al., 2003; Erskine et al., 
2014; Esplen et al., 2007; Etchegary et al., 2014). Unlike hereditary cancers and 
most inherited heart conditions, the subtype of ARVC being studied here is 100% 
penetrant so genetic testing is able to eliminate uncertainty (Merner et al., 2008). 
For this reason, pre-symptomatic testing may be highly valuable to ARVC patients in 
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terms of preventative measures, since the outcome has a level of certainty that 
many other hereditary conditions do not have. 
Those who have experienced a critical event such as the death of a family 
member or the onset of the symptoms are much more likely to opt for genetic 
testing (Armstrong et al., 2000; Cox, 2003; d'Agincourt-Canning, 2005; Etchegary, 
2006; Etchegary, Lemyre, & Wilson, 2010; Kasparian, Meiser, Butow, Simpson, & 
Mann, 2009; Klitzman, Thorne, Williamson, Chung, & Marder, 2007; Manuel & 
Brunger, 2014; McAllister, 2002; Norris, Spelic, Snyder, & Tinley, 2009; Smith, 
Michie, Stephenson, & Quarrell, 2002) . As previously referenced, the onset of 
symptoms increases perception of personal risk and greater perceived risk tends to 
increase likelihood of opting for genetic testing. Those who are affected by ARVC 
have typically witnessed the death of relatives and are aware of the severity 
(Etchegary et al., 2014). 
Most individuals at risk for the subtype of ARVC under examination here 
describe their decision to be tested as something that “had to be done” rather than a 
“decision” (Etchegary et al., 2014).  
 
Reaction to Status and Psychosocial Adjustment 
 
 Owing to small populations and lengthy study follow-up, the long-term 
harms and benefits of genetic testing remain underexplored (Rew, 2010). Results 
from a small number of studies have shown conflicting results; however, the 
majority show that individuals diagnosed with hereditary conditions do not 
experience negative psychosocial effects, at least in the short term.  
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 As with any hereditary condition, genetic testing for ARVC is often a family 
decision and coping with the results is a collaborative process (Manuel & Brunger, 
2014) . It has been shown that availability of social support is associated with better 
psychosocial adjustment to a positive gene test (Lapointe et al., 2013). Depending 
on the level of psychosocial support available, receiving genetic test results can 
range from being very stressful to being a non-event (Cox, 2003). Low levels of 
social support have previously been shown to increase psychological distress in 
those undergoing genetic counselling (Bjorvatn, Eide, Hanestad, & Havik, 2008; 
Esplen et al., 2007; Lammens et al., 2010; Schlich-Bakker et al., 2006) . 
 Some studies have shown that gene carriers experience psychosocial distress 
immediately following diagnosis but show no evidence that these effects are long 
lasting (Aatre & Day, 2011; Baumann, 2006; Broadstock, Michie, & Marteau, 2000; 
Collins et al., 2007; Lapointe et al., 2013; Lerman, Croyle, Tercyak, & Hamann, 2002) . 
These studies provide evidence for some distress immediately following diagnosis 
but subsiding with time. These negative emotions however, may return at transition 
points in one’s life such as marriage or deciding to have children when the result of 
the gene test is again relevant (Aatre & Day, 2011) . Other studies have failed to find 
evidence that a positive gene test causes any significant psychosocial distress (Bonis 
et al., 2007; Broadstock et al., 2000; Eijzenga, Hahn, Aaronson, Kluijt, & Bleiker, 
2014; Foster et al., 2007; Heshka, Palleschi, Howley, Wilson, & Wells, 2008) . Some 
causes of distress throughout the testing process and after testing include anxiety 
while waiting for test results, the burden of regular medical exams, and the burden 
of knowing (Broadstock et al., 2000; Collins et al., 2007; Croyle, Smith, Botkin, Baty, 
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& Nash, 1997; J. G. Hamilton, Lobel, & Moyer, 2009) . Some individuals who are 
phenotype negative and genotype positive, especially those who are otherwise 
healthy, find the concept difficult to comprehend which can lead to some level of 
distress following testing (Ormondroyd et al., 2014).  
Several factors have been determined to increase the risk of negative 
psychosocial effects in hereditary cancers including young age (Bjorvatn et al., 2008; 
Schlich-Bakker et al., 2006), previous cancer diagnosis (Douma et al., 2010; 
Kasparian, Meiser, Butow, Simpson, & Mann, 2008; Keller et al., 2008) , and 
experience of cancer in close relatives (Turner-Cobb, Bloor, Whittemore, West, & 
Spiegel, 2006) , and avoidant coping style (Esplen et al., 2007; Mellon et al., 2008; 
Schlich-Bakker et al., 2006). Similarly, for hereditary cardiac conditions, previous 
experience with a life-threatening arrhythmia, high level of anxiety about the 
condition, and uncertainty about prognosis have been found to be predictors of poor 
psychosocial adjustment(Carroll, Hamilton, & McGovern, 1999) . 
 Despite the potential negative effects, the purpose of genetic counselling and 
testing is to reduce uncertainty and increase perceived control over future health. 
Several studies have shown a decrease in depression and anxiety as a test result, 
regardless of the outcome, eliminates uncertainty(Aatre & Day, 2011; Bonis et al., 
2007) . Aatre (2010) found that non-carriers experienced relief, while positive 
carrier status did not compound existing distress and anxiety. One study of HBOC 
found that a positive test result validated an individual’s concerns, allowed 
individuals to mentally prepare for the onset of disease, and increased access to 
surgical options (Lim et al., 2004). Similarly, a study of LS found that 89% of 
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individuals who tested positive experienced instrumental advantages (e.g. access to 
treatment) and 33% experienced a reduction in uncertainty (Claes et al., 2004).  
 Outcomes of those who test negative for a disease-causing gene are 
conflicting. In a study of individuals at risk for LS, 50% of those who tested negative 
felt reassured by the result and 39% felt reassured that they would not put their 
children at risk (Claes et al., 2004). However, in the same study, it was found that a 
large number of people expressed difficulties arising from having different results 
than family members such as survivor guilt, feelings of exclusion and negative 
reactions from relatives. These results are consistent with studies of inherited 
cardiac conditions (Aatre & Day, 2011; Claes et al., 2004; d'Agincourt-Canning, 
2006; Schwartz et al., 2002) . 
 Most of the relevant literature is focused on hereditary cancers, but cardiac 
conditions are different for several reasons: treatments exist for the prevention of 
SCD, a positive test result could be of immediate concern, these conditions more 
commonly affect individuals under the age of 18, and lifestyle may be significantly 
affected (Ormondroyd et al., 2014). Consequently, genetic testing may be of 
particular importance to minors. There have been conflicting results in studies of 
psychosocial distress in minors undergoing genetic testing but overall, it has been 
found that children cope well with genetic testing(Aatre & Day, 2011) . Initial 
reactions immediately following testing are similar to adults: guilt, worry, anger, 
and fear, but also a sense of decreased uncertainty (Rew, Mackert, & Bonevac, 
2009) . Overall, at risk children do not experience high levels of psychological 
distress (Codori, Petersen, Boyd, Brandt, & Giardiello, 1996; Codori et al., 2003; 
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Michie, Bobrow, & Marteau, 2001; Smets et al., 2008) . Particularly with inherited 
heart conditions, children tend to be articulate about their condition, and being able 
to explain their condition to peers reduces social isolation and increases social 
support (Aatre & Day, 2011) . However, like adults, when children reach transition 
points later in life, negative reactions to testing are often revisited and individuals 
who were tested as young children may experience resentment over not being 
included in the decision making process (Manuel & Brunger, 2014) . 
 Negative psychosocial effects may also appear in carriers after testing in 
response to treatment or life changes resulting from the testing outcome. The need 
for medications, implantation of an ICD, the psychosocial implications of which are 
also conflicting, and the possibility of early death may affect educational and 
professional goals, as well as intimate relationships (Aatre & Day, 2011; Friedmann 
et al., 2006; Hamang et al., 2010) .  
 
Communication About ARVC Risk 
 
Communication is a key element in maintaining relationships and social 
support networks. Sharing genetic information has been shown to strengthen family 
relationships (Lapointe et al., 2012; van Oostrom et al., 2007).  More open family 
discussions surrounding genetic status have been associated with greater levels of 
social support and greater social support has, in turn, been shown to improve 
psychosocial adjustment (Bowen, Bourcier, Press, Lewis, & Burke, 2004; den Heijer 
et al., 2011; van Oostrom et al., 2007) . However, understanding communication 
between family members can be complicated as family members receive different 
results (Hamann et al., 2008; Peterson et al., 2003).  The disclosure of one’s test 
 32 
results can be burdensome, particularly for the proband as they may feel a 
responsibility to inform the rest of the family (Bakos et al., 2008; Carlsson & Nilbert, 
2007; Di Prospero et al., 2001; Hallowell, 2006) . One study has shown that carriers 
tend to have more difficulty sharing their results, and that carriers tend to share 
their results with fewer people than do non-carriers (Lapointe et al., 2013). A 
positive gene result often has implications for non-relatives including partners and 
spouses, as the need for treatment and the possibility of early death may influence 
personal, educational, and financial goals, as well as the development of intimate 
relationships (Aatre & Day, 2011) .  
For parents who test positive for hereditary conditions, there is the added 
complication of transmission guilt (Aatre & Day, 2011) . When dealing with 
hereditary heart conditions where there is a real risk of SCD, disclosure of risk to a 
child with aspirations of a physically demanding career could be devastating (Aatre 
& Day, 2011) .  
A negative gene test may also lead to survivor’s guilt in individuals who have 
other relatives who are carriers (Carlsson & Nilbert, 2007; d'Agincourt-Canning, 
2006; Hallowell, 2006) .  
Regardless of result, some individuals do not feel supported by family 
members with differing results, making psychosocial adjustment more difficult 
(Appleton, Fry, Rees, Rush, & Cull, 2000; Frost, Venne, Cunningham, & Gerritsen-
McKane, 2004; R. Hamilton & Hurley, 2010; Lim et al., 2004) . 
While family dynamics influence how results are communicated, the duty to 
warn is a consistent theme among many studies of hereditary conditions (Aatre & 
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Day, 2011; Pullman & Hodgkinson, 2006) .  In qualitative studies of individuals in 
Newfoundland and Labrador at risk for ARVC, the majority hold the opinion that 
genetic testing is a positive thing and should be pursued where intervention is 
available (Etchegary et al., 2014).  
 
Discussion of Literature 
 
 While there is a significant body of literature surrounding the psychosocial 
impact of hereditary cancers, little research has been conducted on those at risk for 
cardiomyopathies, particularly ARVC. Individuals with cardiomyopathies may have 
unique anxieties due to the risk of SCD, an imminent danger for some individuals 
who test positive for TMEM43. Unlike many hereditary conditions, ARVC caused by 
TMEM43 is 100% penetrant, and SCD is a common symptom (Merner et al., 2008). 
When compared to other inherited heart conditions, including Long QT Syndrome 
and Hypertrophic Cardiomyopathy, this subtype of ARVC has a much higher risk of 
death, which may result in a significantly different psychosocial impact(Jackson, 
Huisman, Sanatani, & Arbour, 2011; Maron & Maron, 2013; Merner et al., 2008; 
Murray, 2012; Ventura, Napolitano, Buquicchio, Cecere, & Arsieni, 2012) . 
However, as shown in Table 1, ARVC shares a number of key characteristics 
with the conditions discussed above. All the conditions discussed above commonly 
follow an autosomal dominant inheritance pattern with the exception of some less 
common subtypes, as well as variable expressivity, and treatment options. 
Uncertainty is a common theme throughout studies of the psychosocial impact of 
hereditary disease; conditions with the same inheritance pattern and variable 
expressivity should be similar in level of uncertainty.  
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Table 1: Comparable inherited conditions 
Condition Inheritance Pattern Life Expectancy or 
risk of death  
Penetrance Expressivity Treatment 
Available 
ARVC caused by 
p.S358L TMEM43 
Autosomal dominant 
(Hodgkinson, 2013) 
41 years in males, 71 
years in females 
(untreated) (Merner et 
al., 2008) 
100%  (Merner 
et al., 2008) 
Variable in both 
males and females, 
but more 
malignant in males 
Implantable 
cardioverter 
defibrillator 
(ICD) 
ARVC in general Autosomal dominant or 
recessive depending on 
causative gene (Murray, 
2012; Towbin, 2008)  
Variable (Murray, 
2012) 
30% - 50%  
(Towbin, 2008) 
 
Variable (Murray, 
2012) 
ICD/Antiarrhyth
mic medication, 
beta blockers 
Long QT Syndrome Autosomal dominant or 
autosomal recessive 
depending on gene. 
(Vincent, 1998) 
Risk of death 15% to 
70% depending on a 
number of factors  
Incomplete 
(Vincent, 1998) 
Variable (Vincent, 
1998) 
Oral 
medications, 
ICD in some 
cases  
Hypertrophic 
Cardiomyopathy 
Autosomal dominant 
(Maron & Maron, 2013)  
Risk of death 1% when 
treated (Maron & 
Maron, 2013)  
 
Incomplete 
(Maron & Maron, 
2013)  
Highly variable 
(Maron & Maron, 
2013)  
Oral 
medications, 
ICD in some 
cases  
Lynch Syndrome 
(HNPCC) 
Autosomal Dominant 
(Kopciuk et al., 2009) 
Variable (Kopciuk et al., 
2009) 
98% for men, 
93% for females 
by age 70 
(Kopciuk et al., 
2009) 
Variable (Kopciuk 
et al., 2009) 
Treatment for 
identified cancer  
Hereditary Breast and 
Ovarian Cancer 
(HBOC) 
Autosomal Dominant or 
Autosomal recessive 
depending on causative 
gene (Rainville & Rana, 
2014)  
Variable (Rainville & 
Rana, 2014) 
20%-90% 
depending on 
causative gene 
(Rainville & 
Rana, 2014)   
Variable (Rainville 
& Rana, 2014) 
Treatment for 
identified cancer  
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Among the conditions discussed above, hereditary cancers are the most 
similar in terms of penetrance, one of the factors that distinguish this subtype of 
ARVC from the other conditions (Kopciuk et al., 2009; Rainville & Rana, 2014) . LS 
has a penetrance higher than 90% and has also been studied in the Newfoundland 
population; therefore, it might also be similar in psychosocial impact. It is believed 
that psychosocial surveys developed for use in LS populations will be relevant for 
ARVC populations. 
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CHAPTER 3 
 
Methodology 
 This pilot study was a part of a larger study investigating a number of key 
molecular and GE3LS (Genomics-related Ethical, Environmental, Economic, Legal 
and Social) issues associated with SCD in Newfoundland and Labrador.  Appendix A 
outlines the GE3LS research program and where this project fits in the broader 
research context. This particular study is a quantitative follow-up to qualitative 
research recently completed by Etchegary et al (2014). The primary goal of the 
current study was to examine the reliability and validity of two psychometric testing 
tools previously developed for LS for use in the ARVC population. The secondary 
goal was to identify clinical factors that may potentially be associated with the 
psychosocial impact on individuals at risk for ARVC.  
 
Development of HD-GT and PAHD Scales 
Development of Scales for Lynch Syndrome 
 To create the original scales developed for LS, survey items were generated 
using a qualitative database created during interviews with members of eight 
different LS families. The list of items was refined by removing items that were 
unclear, contained jargon, or contained negative wording. A common likert scale 
was applied to each item, with responses ranging from 0-4 (not at all to extremely). 
Once the list was refined and wording was clarified, items were reviewed for 
content and usefulness of the rating scales by two genetic counsellors familiar with 
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LS families, a carrier of the gene, and a non-carrier of the gene.  Items were 
subsequently reworded to remove ambiguity (LeDrew, 2009; Way et al., 2011).  
 Readability was then assessed using the Flesch-Kincaid Grade Level and 
Flesch Reading Ease, SMOG (Simple measure of gobbledygook), and the Fog Index. 
Scales were determined to be at a grade 9 level and therefore met readability 
criteria.  
 These scales were chosen for this study because they were developed locally 
and within a local context. The populations LS and ARVC populations are 
homogenous, island populations with an evident founder effect and contain large 
families.  Because of the strength of development of both scales for local families, we 
wanted to know if their use could be extended to other families with an autosomal-
dominant condition. While other psychosocial instruments are available in the 
literature (e.g. Genetic Psychosocial Risk Instrument, Genetic Risk Assessment 
Coping Evaluation, etc) the two scales under study were chosen due to the 
similarities in local context and the relation of themes explored within the scales to 
qualitative work with ARVC families. 
Modification of Scales for ARVC 
 Members of the supervisory committee first met with the original scale 
developers to begin discussion about whether and how tools might be modified for 
use in the ARVC population. This meeting included Drs. Hodgkinson, Etchegary, and 
Pullman from the ARVC study team, as well as Drs. Chris Way and Kathy Watkins 
from the School of Nursing, Memorial University who had created the scales for use 
in LS populations. There was agreement in principle to avoid duplication of effort 
 38 
and that demonstrating generalizability of the tools to another inherited condition 
would be useful. In order to be as transparent as possible, the team held a series of 
meetings to discuss issues of wording and to change any items not applicable to 
ARVC. Where possible, exact wording was maintained. The team also discussed the 
population to which surveys would be sent (e.g., those who had undergone genetic 
testing), as well as practical and logistical issues with survey mail outs. After three 
meetings, two items were removed and several items were modified, but the 
meaning of items was consistent. For example, questions about screening were 
changed to reflect the differences in screening between cancer and heart conditions, 
but the purpose of the questions remained the same. Prior to analysis, any items not 
included in the final, validated versions of the scales for LS were also removed from 
the ARVC versions for future comparability. Original versions of surveys, modified 
for ARVC, were sent to study participants are included in appendix B (HD-GT) and 
appendix C (PAHD).  
Scale Readability  
 Measures were taken to assure an appropriate reading level for all 
participants. In their original forms for use in LS, both scales were determined to be 
at a 9th grade reading level to assure maximum comprehension. Modification of the 
scales for use in the ARVC population did not affect readability. Since all participants 
have previously undergone genetic testing for ARVC, they have been exposed to the 
terms carrier/non-carrier, inherited, generation, geneticist/genetic counsellor, ECG, 
Holter monitor, etc. Terms such as these increase the overall readability scores but 
would be familiar to all participants.  
 39 
Psychometric Evaluation of Scales 
Population and Sample 
The target population for this study was individuals born at an a priori 50% risk 
for the TMEM43 mutation known to cause ARVC who had undergone genetic testing.  
Survey respondents were recruited from an ARVC dataset maintained by members 
of the ARVC research program, Drs. Kathy Hodgkinson and Susan Stuckless. The 
dataset contains a large number of clinical variables for each member of the 24 
Newfoundland and Labrador families identified as having a history of ARVC.  
Individuals who were excluded from the study include those who were not born at 
50% a priori, were under the age of 14, did not have a well-ascertained sibship (see 
figure 1), had died since the last dataset update, had no contact information 
available, or had previously refused to be contacted for research purposes. Whole 
families were also excluded if the ARVC gene had recently been identified. 
Individuals in these families would have been going through the genetic testing 
process and dealing with the diagnosis at the time of the study, so it was decided 
that it would be in the best interest of the families to be excluded from this phase of 
the project.  
The version of the dataset used for analysis contains information for 885 
individuals. In total, 238 individuals were contacted, representing approximately 
half of all living individuals in the dataset, 176 agreed to participate in the study and 
73 returned completed surveys and consent forms (41% overall response rate).   
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Figure 1: Representative pedigree of an ARVC family, illustrating the method used to remove ascertainment bias  
*License for use of copyrighted material included in appendix F.
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Due to the fact that the dataset is not linked to vital statistics, deaths are not 
always captured in a timely fashion. Attempts were made to contact four individuals 
who had died since the dataset was last updated.  
Four individuals with unknown or unconfirmed gene status were also contacted; 
however, none returned the survey package and were not included in the analysis. 
The majority of individuals with unknown gene status are unknown because they 
have not gone through testing at the cardiac clinic in St. John’s and thus, their 
contact information was not available to the research team. Figure 2 summarizes 
the recruitment process. 
Procedure 
Recruitment and data collection began following receipt of ethical approval 
from the Health Research Ethics Authority (approval of final amendment approval 
included in appendix E). Initial contact with potential study participants was made 
via telephone by a genetic counsellor or a representative of the genetics team. Those 
who agreed to receive a survey package verbally gave consent to be contacted for 
follow up by other members of the research team. Participating parents with 
children aged 14 to 18 years were also given the opportunity to volunteer their 
children provided the child(ren) met all other inclusion criteria. It was thought that 
youth would have a unique perspective that would be valuable to the study, but that 
the child’s willingness and ability to complete the survey would be at the discretion 
of the parent. Participants were given the choice between a paper copy of the survey 
package and an emailed fillable PDF version of the survey package.  
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No 
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N=49 
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N=30 
No 
N=50 
Yes 
N=0 
No 
N=4 
Yes 
N=92 
No 
N=21 
Yes 
N=80 
No 
N=37 
Yes 
N=4 
No 
N=0 
Figure 2:  Recruitment flow chart 
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If surveys were not received within four weeks of dispatch, participants were 
called by a member of the research team to check the surveys had been received. 
Those who did not receive the study package were sent a second copy by mail. 
Those who had received the surveys and had not filled them out or had not yet sent 
them back were thanked for their participation. In the case of those who could not 
be reached (no answer or call was answered by someone else and participant was 
not available), repeat calls were made one week apart to a maximum of four calls. To 
maintain participant privacy, no messages were left.  
HD-GT Scale  
The original version of the HD-GT scale modified for ARVC contained 10 
sections and 63 items. This content of this scale guides participants through the 
journey from learning about risk, to becoming aware of genetic testing and making a 
decision, and finally to the process of testing.  
The first section focuses on learning about risk and how ARVC risk affects 
familial relationships (e.g. “It was scary to see the same pattern of early sudden 
cardiac death showing up in every generation of my family”.) 
The second section focuses on becoming aware of available genetic testing. 
This section was removed following final validation in LS populations and was 
therefore not included in analysis for this study.  
Sections 3 through 10 capture attitudes toward genetic testing at various 
stages of the process. Sections 3 and 4 examine emotional preparedness (e.g. It is 
important to know if one has the ARVC gene to help children/grandchildren) and 
struggling with relatives who refuse testing (e.g. “I feel obligated to encourage 
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family members who refuse genetic testing to rethink their decision”). Section 5 
looks at wait time considerations, but was excluded from the final LS scale and was 
therefore excluded from analysis for this study. Sections 6, 7, 9 and 10 are designed 
to measure perceived adequacy of clinical and social support (e.g. “It is important to 
have face-to-face contact with a geneticist/genetic counsellor when receiving your 
results”), preparedness for results (e.g. “Knowing whether or not I had the ARVC 
gene for early sudden cardiac death brought a sense of closure to everything”), 
awareness of risk and inheritance patterns (e.g. Men and women seem to be affected 
differently), and issues of disclosure to other family members (e.g. “In our family, we 
struggle with knowing when to tell young family members about early sudden 
cardiac death”). Section 8 was also removed as it was not included in the final LS 
version.  
PAHD Scale 
 The PAHD scale modified for ARVC contains two sections: burden of knowing 
(BK) and family support in ARVC (FSARVC).  This scale aligns closely with the 
content of the first section of the HD-GT, but examines the concepts of living with 
risk and managing family relationships in more detail. Examples of some items in 
this scale include “I think about being a carrier/non-carrier more than I should” and 
“I worry that all the suffering and death from ARVC is placing too much burden on 
family members”.  
Ethical Considerations  
 Measures were taken to maintain participant privacy and confidentiality at 
each step of the process. Individuals were initially contacted by a genetic counsellor 
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or a representative with whom they had previously had contact. Those who agreed 
to participate agreed to have contact information released to the research team for 
the purpose of follow up. As part of the study package, each participant was also 
sent a detailed description of the study as well as a consent form. Only those who 
returned completed consent forms were included in analysis. The consent form 
confirmed that participants understood the purpose of the study, the potential risks 
involved, and that a genetic counsellor would be available to respond to any 
concerns that may arise from the survey questions. Contact information for a 
genetic counsellor was included so that it would be accessible to participants while 
completing the surveys.  
Surveys were tracked using only a patient ID. A separate list linking patient 
ID to patient contact information was kept in a locked cabinet within an office 
accessible only to the research team and did not leave the room at any time. During 
follow up calls, members of the research team did not leave messages and did not 
discuss the reason for the call with anyone other than the survey respondent. In a 
small number of cases, family members who answered the phone were worried that 
the reason for the call was a problem with test results. In cases such as these where 
the study participant was not available, the family member was told only that the 
call was for research purposes, to relieve anxiety.  
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Data Analysis  
 Data were entered into the IBM SPSS Statistics for Mac, version 22 for 
analysis. Analysis was broken into two segments: 1) survey validation and 2) 
exploration of psychosocial impact. 
The first validation step involved using descriptive statistics to confirm 
approximate equivalence of means and variances for each item as well as each scale. 
Scales were constructed by summing appropriate items and removing missing data. 
The second validation included multi-item/multi-trait correlation matrices to test 
assumptions of linearity, item-convergent validity, and item-discriminant validity. 
Each step is explored in detail in the following chapter.  
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CHAPTER 4 
Results 
 Study findings are presented in three sections.  1) The first section 
summarizes descriptive statistics for the study as a whole and for each survey tool. 
2) The second section provides reliability and validity data for each survey tool used 
in the Newfoundland ARVC population. 3) The third provides a brief overview of 
preliminary psychosocial findings. 
Descriptive Profile of Participants 
A total of 73 individuals participated in this pilot; 43 individuals (59%) were 
TMEM43 carriers and 30 (41%) were not. The majority of respondents were female. 
Table 2 summarizes the descriptive statistics for study participants. 
Table 2: Descriptive profile of survey participants 
 N % 
Sex   
Male 19 26.0 
Female 54 74.0 
Sex of transmitting parent   
Male 34 46.6 
Female 37 50.7 
Unknown 2 2.7 
 
Positive for TMEM43 gene 
  
Yes 43 58.9 
No 30 41.1 
 
Subscale Structure 
 
Following removal of any items not included in the final LS version of the HD-
GT scale, items were organized into nine subscales: Impact of ARVC (IARVC), Family 
Challenges in Genetic Testing (FCGT), Genetic Testing Preparation (GTP), Wait Time 
Concerns (WTC), Support with Genetic Testing Results (SGTR), Understanding Risk 
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(UR), Transmission Beliefs (TB), Communication Around Genetic Link (CGL), and 
Disclosure Issues (DI). 
Similarly, items from the PAHD scale were organized into two subscales: BK 
and FSARVC. 
Data Quality 
 Tables 3 and 4 summarize item-level descriptive statistics for the HD-GT and 
PAHD scales, respectively. Missing data for both scales were minimal, ranging from 
0% to 4.1%, and random, indicating there were no significant issues of question 
interpretation. All responses were used in all items with the exception of items 
related to the importance of healthy living and one item related to understanding of 
the gene, where the “not at all” option was not used. These items refer to uncommon 
states (believing that healthy living is not important to overall well-being, and 
family members not having an understanding of the ARVC gene) and therefore one 
would not expect a full range of responses (Ware & Gandek, 1998) . The frequency 
distribution was also skewed in GTP, FCGT, and UR sections. These results were 
expected as participants have all participated in genetic testing and are more likely 
to attach a high importance to understanding risk, undergoing testing, and 
encouraging family members to be tested. 
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Table 3: Item Level Descriptive Statistics HD-GT Scale 
 
Item Mean SD Missing  
(%) 
Response Values Frequency 
0 1 2 3 4 
Scale:  Impact of ARVC (IARVC)         
A1.1_R: SCD more frequent and younger 1.35 1.39 2.7 25 21 9 7 9 
A1.2_R: Memories of close family members dying young 1.58 1.50 2.7 26 11 12 11 11 
A1.3_R: Presence of SCD hard to accept 1.41 1.47 2.7 29 12 12 8 10 
A1.4_R: Scary to see pattern of SCD every generation 1.29 1.36 4.1 27 19 8 9 7 
A1.5_R: Draining to lose relatives 2.06 1.64 2.7 20 11 6 13 21 
A1.6_R: Worry about own health and death 1.80 1.52 2.7 20 13 15 7 16 
A1.7_R: Worry about other types of heart disease showing up 2.50 1.46 4.1 8 14 10 11 27 
Scale: Genetic Testing Preparation (GTP)         
A3.1: Getting enough information in a timely manner 3.13 1.00 2.7 2 2 13 22 32 
A3.2: Receiving enough information about the process 3.15 0.90 2.7 0 3 15 21 32 
A3.4: Knowing if one has the ARVC gene 3.57 0.73 4.1 0 2 4 16 48 
A3.5: Understanding one’s risk and accepting need for testing 3.55 0.77 2.7 1 0 6 16 48 
A3.6: Knowing if one has the gene for children/grandchildren 3.61 0.96 2.7 3 1 3 7 57 
Scale: Family Challenges Genetic Testing (FCGT)         
A4.1: Important for all family members to take part in testing 3.77 0.70 0 1 0 5 3 64 
A4.2: Concern about family members who refuse testing 3.30 1.18 4.1 5 2 5 13 45 
A4.3: Family members who refuse do not understand risk 3.01 1.32 1.4 7 3 10 14 38 
A4.4: Family members who refuse are fearful of result 3.47 0.80 0 1 0 8 19 45 
Scale: Wait-time Concerns (WC)         
A5.1_R: Trying thinking about the gene 1.46 1.49 2.7 28 13 9 11 10 
A5.2_R: Not prepared for such a long wait time 2.63 1.30 2.7 4 12 17 11 27 
A5.3_R: Unsure about how results would be received 3.12 1.17 1.4 3 6 9 15 39 
A5.4_R: Spent a lot of time thinking about own reaction 2.23 1.60 2.7 15 13 9 9 25 
A5.5_R: Wondering if one would understand meaning of result 2.39 1.44 1.4 8 15 16 7 26 
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Scale: Support for Genetic Testing Results (SGTR)         
A6.1: Having a family member present 2.31 1.55 1.4 16 6 14 12 24 
A6.2: Receiving phone call from geneticist/genetic counsellor 
prior to receiving results 
2.18 1.38 1.4 13 7 22 14 16 
A6.3: Face to face contact when receiving results 1.42 1.42 1.4 9 3 12 10 38 
A6.4: Receive letter explaining meaning of carrier/non-carrier 2.92 1.40 0 9 5 5 18 36 
Scale: Understanding Risk (UR)         
A8.1: Regular monitoring will detect disease at early stage 3.41 1.04 0 4 0 6 15 48 
A8.2: Appropriate monitoring important for timely detection 3.71 0.54 0 0 0 3 15 55 
A8.3: Early detection will help treatment and management 3.77 0.51 0 0 0 3 11 59 
A8.4: Healthy living & positive attitude will increase well-being 3.62 0.68 0 0 1 5 15 52 
A8.5: Taking responsibility for healthy living & monitoring 3.64 0.59 0 0 0 4 18 51 
Scale: Transmission Beliefs (TB)         
A9.1: Family members affected at younger age 2.73 1.34 2.7 7 7 12 17 28 
A9.2: Men and women affected differently 2.83 1.19 1.4 5 6 9 28 24 
A9.3: Different types of heart disease showing up more 2.58 1.35 2.7 7 11 10 20 23 
A9.4: Number of affected family members greater 2.50 1.36 4.1 9 8 12 21 20 
Scale: Communication around Genetic Link (CGL)         
A10.3: Young family members open to information about gene 2.28 1.08 2.7 2 16 25 16 12 
A10.4: Young family members understand what the gene means 2.18 1.05 2.7 4 14 25 21 7 
A10.7: Family members open to information about gene 3.01 0.93 2.7 1 4 12 30 24 
A10.8: Family members understand what the gene means 2.89 0.93 4.1 0 6 16 28 20 
Scale: Disclosure Issues (DI)         
A10.2: Difficult to tell younger family members 2.24 1.52 2.7 13 14 8 15 21 
A10.6: Hard telling family members about possible risk 2.85 1.19 2.7 3 8 14 18 28 
A10.9: Helpful for family messenger to have guidance/support 
from geneticist/genetic counsellor 
2.97 1.10 2.7 1 6 19 13 32 
A10.10: Important to protect the rights of others 3.20 1.14 2.7 4 2 10 15 40 
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Table 4: Item Level Descriptive Statistics PAHD Scale 
 
Item Mean SD Missing  
(%) 
Response Values Frequency 
0 1 2 3 4 
Scale: Burden of Knowing (BK)     
B1.1_R: Think about being carrier/non-carrier 2.14 1.47 1.4 13 15 11 15 18 
B1.4_R: Hard changing frequency of monitoring 2.99 1.25 1.4 4 6 14 11 37 
B1.5_R: Bothered by others not accepting status 3.18 1.35 1.4 8 1 8 8 47 
B1.7_R: Hard to deal with young family members with 
gene 
1.96 1.55 1.4 18 14 12 9 19 
B1.8_R: Worry about future of young family members 1.29 1.40 1.4 30 16 8 11 7 
B2.4_R: Presence of SDC has hurt family relations 2.90 1.41 1.4 6 10 8 9 39 
B2.5_R: Worry that ARVC placing too much burden on 
family 
1.81 1.32 1.4 13 20 18 10 11 
Scale: Family Support in ARVC (FSARVC)     
B2.1: Feeling supported by family & friends has 
helped accept status 
2.72 1.20 2.7 5 6 15 23 22 
B2.2: Easy to seek help from family 2.69 1.27 2.7 6 6 17 17 25 
B2.3: Important to talk openly about SCD risk 2.99 1.13 1.4 2 4 22 9 35 
B2.6: Providing care for family has helped accept the 
future 
1.74 1.36 1.4 19 12 19 13 9 
B1.6: Young people need to be encouraged to talk 
about SCD 
2.80 1.21 0 4 7 17 17 28 
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Item Level Scale Assumptions 
Within each subscale, mean and standard deviation were approximately 
equal with few exceptions. This indicates that overall, data were not skewed and 
responses were normally distributed. 
Two items, A1.7 and B2.6, with outlying means highlight the differences 
between ARVC and cancer.  The first asks about worry of other types of heart 
disease appearing in those who test negative for the ARVC gene. The genes 
associated with LS put an individual at increased risk for several types of cancer, but 
those without the gene can also develop cancer. Conditions similar to ARVC are 
much more uncommon than cancer, so individuals who test negative for an ARVC 
gene do not typically develop a related condition. The second item has to do with 
family members coming to accept their own future by acting as a caregiver for 
another family member with the condition. Individuals with ARVC do not typically 
require ongoing care from friends or family members so this type of relationship, 
which can be common with cancer, is relatively uncommon with ARVC.  
Some items have inherently skewed means. One example is item B1.8 that 
deals with concern for young family members. Within families, individuals tend to 
place more importance on the health of younger family members, particularly 
children and grandchildren, than on their own health. Compared to other family 
relationships, individuals tend to place more importance on younger family 
members.  Similarly, item 5.1, dealing with the impact of uncertainty while waiting 
for test results has a different mean than other items in the scale.  The other items in 
the scale deal with uncertainties about how the results will be received and are 
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much less emotionally charged. Another item with an inherently skewed mean is 
A6.4, which deals with the importance of receiving a letter detailing test results and 
the meaning of the result. Individuals going through a stressful event such as genetic 
testing may forget details or may not fully understand all the details when results 
are revealed face to face. Regardless of the specific situation, when receiving a large 
amount of information, a paper copy of the information is often preferred and/or 
expected. 
Overall, there were no major unexplained discrepancies in means or 
variances so the subscale structure was appropriate and data were valid. 
Scale Level Assumptions 
 
Following verification of the subscale structure and data quality, multi-item 
scale scores were computed for each participant by summing scores of the items 
contained within each subscale. Where one or more questions were omitted, the 
individual was excluded from analysis of that particular subscale. Between zero and 
six individuals (0% - 8%) were excluded from a given scale for this reason. 
Summated scores can be used successfully under the Likert scaling 
assumptions (Ware & Gandek, 1998) . The three assumptions are as follows: 1) 
items in each grouping should contribute approximately the same amount of 
information to the subscale, 2) items should have approximately equal variances 
within each subscale, and 3) items should be linearly related to the subscale score 
(Likert, 1932). The second assumption has already been made based on the 
descriptive statistics provided above. Assumptions one and three can be verified 
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using a multi-trait/multi-item correlation matrix. Tables 5 and 6 contain these 
findings for the HD-GT survey and PAHD survey, respectively.   
Item Internal Consistency 
 Item internal consistency is the measure of how well an item linearly 
correlates to its subscale score. This value is computed by removing the item in 
question from its subscale, calculating a summated scale score from the remaining 
items, and then computing the Pearson correlation coefficient of the item with the 
new summated score. A correlation is considered statistically significant if the value 
of this correlation is greater than 0.40 (Ware et al., 1980). Most (47) items satisfied 
this condition, four items fell within the 0.30-0.40, and three items fell within the 
0.20-0.30 range. All seven items that fell below 0.40 were related to an extreme so 
they may still be valuable, but may fail the item internal consistency test due to the 
skew to one side. For example, item A9.2 had a correlation value of 0.226, well 
below the 0.40 cut-off. This question was contained in the UR section where 
participants were asked to rate the degree to which the statement reflected their 
families’ situation. This item states “Men and women seem to be affected differently” 
and since ARVC does in fact, affect men and women very differently, the majority of 
participants agreed with the statement. It is a significant aspect of understanding 
risk, but the score for this particular item is not necessarily indicative of a person’s 
overall understanding of his or her risk (the total scale score). Overall, the items 
satisfy the third Likert assumption since they are linearly related to their respective 
subscales.  
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Equality of item-scale correlations  
The correlation values computed in tables 5 and 6 represent the amount that 
each item contributes to its respective subscale. Ideally, items in a given scale will be 
approximately equal and will have a value between 0.40 and 0.70 (Ware & Gandek, 
1998) . Items in the IARVC subscale are approximately equal but have greater values 
than all other scales, with a range of 0.542 to 0.821. With the exception of the items 
with a correlation value lower than 0.40, all other scales are approximately equal 
and are contained within the ideal range.  
Item Discriminant Validity  
While it is important for an item to correlate well with its hypothesized scale, 
it is also important that the same item does not correlate well with any other scale. 
For this study, an item is said to have satisfactory discriminatory power if it 
correlates with its own scale better than another scale by two standard errors. 
Depending on the degree to which an item correlates with its hypothesized scale 
compared to another given scale, a value of 2, 1, -1, or -2 is assigned. A value of 2 
signifies that an item correlates better to its own scale than other scales, and the 
result is statistically significant, a value of 1 signifies that an item correlates better 
to its own scale but the result is not statistically significant. Similarly, a value of -2 or 
-1 is assigned if the item correlates better to another scale than to its own scale.  
Tables 7 and 8 provide summaries of item discriminant validity tests for the HD-GT 
survey and PAHD scale respectively. Item discriminant validities were calculated  
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Table 5: Correlation matrix for HD-GT survey corrected for overlap 
Item Name   Pearson Item-Scale Correlations 
Mean SD IARVC GTP FCGT WC SGTR UR TB CGL DI 
Scale: IARVC            
A1.1_R 1.35 1.39 0.704 -0.167 -0.144 0.109 0.073 -0.072 -0.143 -0.263 -0.115 
A1.2_R 1.58 1.50 0.777 -0.210 -0.252 0.120 0.100 -0.054 -0.295 -0.304 -0.162 
A1.3_R 1.41 1.47 0.821 -0.250 -0.276 0.144 0.017 0.011 -0.281 -0.277 -0.233 
A1.4_R 1.29 1.36 0.744 -0.377 -0.349 0.060 -0.056 -0.147 -0.259 -0.318 -0.119 
A1.5_R 2.06 1.64 0.678 -0.226 -0.370 0.234 0.014 0.018 -0.364 -0.157 -0.209 
A1.6_R 1.80 1.52 0.717 -0.132 -0.187 0.223 0.025 -0.126 -0.385 -0.222 -0.165 
A1.7_R 2.50 1.46 0.542 -0.103 -0.248 0.283 -0.078 -0.291 -0.511 -0.328 -0.228 
Scale: GTP            
A3.1 3.13 1.00 -0.168 0.640 0.280 0.045 0.219 0.164 0.129 0.178 0.283 
A3.2 3.15 0.90 -0.275 0.687 0.370 -0.025 0.284 0.347 0.231 0.383 0.327 
A3.4 3.57 0.73 -0.285 0.605 0.318 -0.141 0.346 0.395 0.194 0.243 0.195 
A3.5 3.55 0.77 -0.242 0.708 0.395 -0.047 0.202 0.281 0.210 0.156 0.279 
A3.6 3.61 0.96 -0.092 0.423 0.355 -0.164 0.298 0.307 0.341 0.255 0.197 
Scale: FCGT            
A4.1 3.77 0.70 -0.292 0.461 0.411 -0.142 0.201 0.421 0.263 0.213 0.355 
A4.2 3.30 1.18 -0.401 0.191 0.491 -0.291 0.188 0.096 0.188 0.229 0.278 
A4.3 3.01 1.32 -0.163 0.418 0.492 -0.061 0.169 0.118 0.287 0.133 0.254 
A4.4 3.47 0.80 -0.220 0.334 0.506 -0.246 0.293 0.149 0.124 0.222 0.236 
Scale: WC            
A5.1_R 1.46 1.49 0.178 -0.257 -0.184 0.629 -0.457 -0.307 -0.151 -0.319 -0.411 
A5.2_R 2.63 1.30 0.115 -0.145 -0.098 0.459 -0.215 -0.347 -0.128 -0.109 -0.195 
A5.3_R 3.12 1.17 0.071 -0.040 -0.205 0.504 -0.209 -0.241 -0.148 -0.175 -0.104 
A5.4_R 2.23 1.60 0.191 0.008 -0.129 0.684 -0.291 -0.255 -0.347 -0.175 -0.170 
A5.5_R 2.39 1.44 0.307 0.023 -0.170 0.573 -0.332 -0.236 -0.392 -0.307 -0.068 
Scale: SGTR            
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A6.1 2.31 1.55 -0.052 0.210 0.406 -0.458 0.414 0.336 0.253 0.323 0.323 
A6.2 2.18 1.38 -0.024 0.229 0.279 -0.347 0.411 0.301 0.015 0.472 0.202 
A6.3 1.42 1.42 0.023 0.356 0.284 -0.266 0.620 0.373 0.037 0.340 0.300 
A6.4 2.92 1.40 0.076 0.265 0.079 -0.114 0.290 0.174 0.009 0.202 0.123 
Scale: UR            
A8.1 3.41 1.04 0.017 0.135 0.017 -0.459 0.346 0.332 0.281 0.266 0.160 
A8.2 3.71 0.54 -0.174 0.439 0.291 -0.248 0.352 0.656 0.293 0.214 0.237 
A8.3 3.77 0.51 -0.249 0.503 0.357 -0.249 0.344 0.630 0.311 0.344 0.120 
A8.4 3.62 0.68 -0.165 0.215 0.112 -0.178 0.267 0.517 0.207 0.373 0.070 
A8.5 3.64 0.59 -0.051 0.229 0.115 -0.086 0.253 0.621 0.155 0.318 0.043 
Scale: TB            
A9.1 2.73 1.34 -0.379 0.438 0.369 -0.282 0.216 0.298 0.539 0.304 0.166 
A9.2 2.83 1.19 -0.107 0.064 0.118 -0.217 -0.044 0.139 0.226 0.049 0.034 
A9.3 2.58 1.35 -0.190 0.051 0.157 -0.132 0.026 0.273 0.456 0.225 0.190 
A9.4 2.50 1.36 -0.389 0.178 0.208 -0.309 0.141 0.225 0.560 0.235 0.191 
Scale: CGL            
A10.3 2.28 1.08 -0.183 0.226 0.162 -0.267 0.421 0.478 0.212 0.683 0.366 
A10.4 2.18 1.05 -0.318 -0.010 0.181 -0.300 0.345 0.260 0.237 0.596 0.216 
A10.7 3.01 0.93 -0.268 0.483 0.406 -0.043 0.413 0.334 0.253 0.620 0.154 
A10.8 2.89 0.93 -0.348 0.458 0.279 -0.281 0.304 0.242 0.244 0.465 0.279 
Scale: DI            
A10.2 2.24 1.52 -0.032 0.206 0.257 -0.152 0.203 0.114 0.172 0.235 0.514 
A10.6 2.85 1.19 -0.188 0.303 0.234 -0.151 0.115 0.052 0.169 0.012 0.522 
A10.9 2.97 1.10 -0.220 0.305 0.347 -0.287 0.426 0.222 0.178 0.294 0.394 
A10.10 3.20 1.14 -0.349 0.224 0.189 -0.135 0.237 0.119 0.104 0.391 0.267 
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Table 6: Correlation matrix for PAHD survey corrected for overlap 
Item Name   Pearson Item-Scale Correlations 
Mean SD BK FSARVC 
Scale: BK     
B1.1_R 2.14 1.47 0.588 -0.453 
B1.4_R 2.99 1.25 0.395 -0.390 
B1.5_R 3.18 1.35 0.424 -0.356 
B1.7_R 1.96 1.55 0.390 -0.149 
B1.8_R 1.29 1.40 0.520 -0.446 
B2.4_R 2.90 1.41 0.465 -0.099 
B2.5_R 1.81 1.32 0.594 -0.343 
Scale: FSARVC     
B2.1 2.72 1.20 -0.433 0.685 
B2.2 2.69 1.27 -0.211 0.536 
B2.3 2.99 1.13 -0.458 0.677 
B2.6 1.74 1.36 -0.381 0.441 
B1.6 2.80 1.21 -0.372 0.464 
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Table 7: Item discriminant validity tests for HD-GT survey 
Item Name   Item-discriminant validity test 
Mean SD IARVC GTP FCGT WC SGTR UR TB CGL DI 
Scale: 
IARVC 
           
A1.1_R 1.35 1.39 n/a 2 2 2 2 2 2 2 2 
A1.2_R 1.58 1.50 n/a 2 2 2 2 2 2 2 2 
A1.3_R 1.41 1.47 n/a 2 2 2 2 2 2 2 2 
A1.4_R 1.29 1.36 n/a 2 2 2 2 2 2 2 2 
A1.5_R 2.06 1.64 n/a 2 2 2 2 2 2 2 2 
A1.6_R 1.80 1.52 n/a 2 2 2 2 2 2 2 2 
A1.7_R 2.50 1.46 n/a 2 2 2 2 2 2 2 2 
Scale: GTP            
A3.1 3.13 1.00 2 n/a 2 2 2 2 2 2 2 
A3.2 3.15 0.90 2 n/a 2 2 2 2 2 2 2 
A3.4 3.57 0.73 2 n/a 2 2 2 2 2 2 2 
A3.5 3.55 0.77 2 n/a 2 2 2 2 2 2 2 
A3.6 3.61 0.96 2 n/a 1 2 1 1 1 1 2 
Scale: FCGT            
A4.1 3.77 0.70 2 -1 n/a 2 1 -1 1 1 1 
A4.2 3.30 1.18 2 2 n/a 2 2 2 2 2 2 
A4.3 3.01 1.32 2 1 n/a 2 2 2 2 2 2 
A4.4 3.47 0.80 2 2 n/a 2 2 2 2 2 2 
Scale: WC            
A5.1_R 1.46 1.49 2 2 2 n/a 2 2 2 2 2 
A5.2_R 2.63 1.30 2 2 2 n/a 2 2 2 2 2 
A5.3_R 3.12 1.17 2 2 2 n/a 2 2 2 2 2 
A5.4_R 2.23 1.60 2 2 2 n/a 2 2 2 2 2 
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A5.5_R 2.39 1.44 2 2 2 n/a 2 2 2 2 2 
Scale: SGTR            
A6.1 2.31 1.55 2 2 1 2 n/a 1 2 1 1 
A6.2 2.18 1.38 2 2 1 2 n/a 1 2 1 2 
A6.3 1.42 1.42 2 2 2 2 n/a 2 2 2 2 
A6.4 2.92 1.40 2 1 2 2 n/a 1 2 1 2 
Scale: UR            
A8.1 3.41 1.04 2 2 2 2 1 n/a 1 1 1 
A8.2 3.71 0.54 2 2 2 2 2 n/a 2 2 2 
A8.3 3.77 0.51 2 2 2 2 2 n/a 2 2 2 
A8.4 3.62 0.68 2 2 2 2 2 n/a 2 2 2 
A8.5 3.64 0.59 2 2 2 2 2 n/a 2 2 2 
Scale: TB            
A9.1 2.73 1.34 2 1 2 2 2 2 n/a 2 2 
A9.2 2.83 1.19 2 1 1 2 2 1 n/a 1 1 
A9.3 2.58 1.35 2 2 2 2 2 2 n/a 2 2 
A9.4 2.50 1.36 2 2 2 2 2 2 n/a 2 2 
Scale: CGL            
A10.3 2.28 1.08 2 2 2 2 2 2 2 n/a -1 
A10.4 2.18 1.05 2 2 2 2 2 1 2 n/a 2 
A10.7 3.01 0.93 2 1 1 2 1 2 2 n/a 2 
A10.8 2.89 0.93 1 1 1 1 1 2 2 n/a 1 
Scale: DI            
A10.2 2.24 1.52 2 1 1 2 1 2 1 2 n/a 
A10.6 2.85 1.19 2 1 2 2 2 2 2 2 n/a 
A10.9 2.97 1.10 2 1 1 2 -1 1 1 1 n/a 
A10.10 3.20 1.14 2 1 1 2 1 2 2 1 n/a 
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Table 8: Item discriminant validity tests for PAHD survey 
Item Name   Item discriminant validity test 
Mean SD BK FSARVC 
Scale: BK     
B1.1_R 2.14 1.47 n/a 2 
B1.4_R 2.99 1.25 n/a 2 
B1.5_R 3.18 1.35 n/a 2 
B1.7_R 1.96 1.55 n/a 2 
B1.8_R 1.29 1.40 n/a 2 
B2.4_R 2.90 1.41 n/a 2 
B2.5_R 1.81 1.32 n/a 2 
Scale: FSARVC     
B2.1 2.72 1.20 2 n/a 
B2.2 2.69 1.27 2 n/a 
B2.3 2.99 1.13 2 n/a 
B2.6 1.74 1.36 2 n/a 
B1.6 2.80 1.21 2 n/a 
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using the statistical program ‘R’ (R Core Team, 2013). Most items demonstrate an 
acceptable discriminatory power. An item may fail the discriminant validity test if it 
correlates well with two or more scales, or if it has a low item-internal consistency. 
Within the IARVC and WC subscales of the HD-GT survey, all items demonstrated 
acceptable discriminatory power. Most of the items that did not receive a value of 2 
were correlated with several scales. Items A6.4, A8.1, A9.2 had a low internal 
consistency which may have resulted in low discriminatory power. Item 3.6 had 
neither low internal consistency nor correlation with other scales, but its mean was 
significantly different than other items in the scale, which may have influenced 
correlation values. Both sub-scales, BK and FSARVC in the PAHD survey 
demonstrated acceptable discriminatory power. 
Reliability and Validity 
The Chronbach’s alpha coefficient was used to determine internal 
consistency of the subscales of each survey tool. These results are summarized in 
tables 9 and 10. A minimum Chronbach’s alpha coefficient of 0.70 is required to 
confirm reliability of a scale (Nunally & Bernstein, 1994) . Four of the nine scales in 
the HD-GT survey fell below this cut-off; however, the range of values for these 
scales was 0.637 to 0.661. Given the relatively small margin, some scales may reach 
the 0.70 cut-off if used in a larger population. Both scales within the PAHD showed 
extremely high levels of internal consistency with coefficients of 0.993 and 0.986. 
All scales had weak, positive correlations with each other except for those that were 
reverse coded; these had weak, negative correlations. One exception was the 
correlation between IARVC and SGTR. As IARVC is reverse coded and SGTR was not,  
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Table 9: Reliability coefficients and inter-scale correlations for HD-GT survey 
Scale IARVC GTP FCGT WC SGTR UR TB CGL DI 
IARVC 0.901         
GTP -0.349 0.812        
FCGT -0.268 0.462 0.651       
WC 0.224 -0.102 -0.219 0.790      
SGTR 0.007 0.410 0.385 -0.436 0.648     
UR -0.140 0.379 0.201 -0.371 0.439 0.736    
TB -0.423 0.278 0.312 -0.325 0.124 0.337 0.661   
CGL -0.340 0.367 0.325 -0.294 0.476 0.424 0.300 0.783  
DI -0.264 0.364 0.361 -0.261 0.342 0.178 0.222 0.329 0.637 
Chronbach’s alpha coefficient is bolded on the diagonal 
 
 
 
 
 
 
 
 
 64 
Table 10: Reliability coefficients and inter-scale correlations for PAHD survey 
Scale BK FSARVC 
BK 0.993  
FSARVC -0.5 0.986 
Chronbach’s alpha coefficient is bolded on the diagonal 
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there should have been a negative correlation, instead, there is a very small (near-
zero) positive correlation.   
All scales also have an alpha coefficient larger than any item’s Pearson 
coefficient.  This finding along with those above demonstrates that each scale 
contributes something unique to the overall survey. 
Psychosocial Analysis 
 Findings discussed above support the reliability and validity of the HD-GT 
and PAHD surveys for use in the ARVC population so the analysis was taken one 
step further to identify potential factors that may influence the psychosocial impact 
of ARVC. Four key factors were examined: sex, parent from whom the gene was 
inherited, carrier status, and age. Sex, carrier status, and age have been discussed in 
the literature as influential factors in terms of attitudes toward genetic testing and 
psychosocial impact of risk. The transmitting parent was also included in this 
analysis due to the drastic difference in how men and women with the TMEM43 
gene are affected. Data for each of the four factors was available for the majority of 
study participants so sample size for the psychosocial analysis was not significantly 
different from sample size for reliability and validity testing.  Tables 11 and 12 
summarize the descriptive statistics for each. Means and variances were 
approximately equal within each subscale, which supports the validity of the scales 
for this analysis.  
An analysis of variance (ANOVA) was conducted using these four factors to 
build a model. Adjusted r squared values for each subscale model ranged from 0 to 
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Table 11: Descriptive statistics for psychosocial analysis of HD-GT survey 
  IARVC GTP FCGT WC SGTR UR TB CGL DI 
Female mean 11.31 17.52 13.75 11.35 11.06 18.24 10.65 10.72 11.65 
n 52 52 51 52 53 54 52 51 52 
s.d 8.24 3.17 2.65 4.96 3.41 2.52 3.77 3.13 3.51 
Male mean 14.00 15.39 13.78 13.22 8.16 17.90 10.59 9.32 10.16 
n 17 18 18 18 19 19 17 19 19 
s.d 8.35 3.40 2.78 5.82 4.84 2.23 3.41 2.93 3.10 
Inherited 
from 
Mother 
mean 14.00 17.14 13.80 11.17 11.32 18.43 10.69 10.05 11.24 
n 35 36 35 35 37 37 35 37 37 
s.d 8.24 3.38 2.82 4.79 3.38 2.32 3.15 2.68 3.27 
Inherited 
from 
Father 
mean 10.22 16.82 13.66 12.24 9.70 17.88 10.41 11.10 11.41 
n 32 33 32 33 33 34 32 31 32 
s.d 7.91 3.38 2.61 5.61 3.99 2.56 4.19 3.23 3.75 
Carrier mean 13.41 16.49 14.00 11.49 11.00 18.21 10.56 10.48 11.58 
n 39 41 39 39 41 42 39 40 40 
s.d 8.03 3.79 2.65 5.32 3.42 2.35 3.63 2.98 3.61 
Non-carrier mean 9.76 17.64 13.59 12.03 9.37 18.00 10.76 10.14 10.90 
n 29 28 29 30 30 30 29 29 30 
s.d 8.18 2.51 2.61 5.07 4.66 2.60 3.83 3.40 3.28 
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Table 12: Descriptive statistics for psychosocial analysis of PAHD survey 
  BK FSARVC 
Female mean 15.73 13.29 
n 51 52 
s.d 6.14 4.75 
Male mean 17.11 11.84 
n 18 19 
s.d 6.46 3.50 
Inherited from 
Mother 
mean 15.69 13.70 
n 35 37 
s.d 6.77 3.93 
Inherited from 
Father 
mean 16.41 12.25 
n 32 32 
s.d 5.78 4.94 
Carrier mean 15.33 13.51 
n 39 41 
s.d 5.95 4.11 
Non-carrier mean 16.83 12.14 
n 29 29 
s.d 6.48 4.94 
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0.190. The IARVC and FSGT had the highest r squared values at 0.156 and 0.190 
meaning that the variables included in the models for these subscales account for 
approximately 16% and 19% of the variance, respectively. The seven remaining 
subscales in the HD-GT survey and the two subscales in the PAHD survey had r-
squared values ranging from 0 to 0.073. Tables 13 and 14 summarize the r squared, 
adjusted beta, and t values for each subscale. Four correlations were found to be 
substantial and statistically significant. First, there was a negative correlation 
between age in years and the IARVC scale. The IARVC scale deals with the 
psychosocial impact of living in a family with ARVC, particularly the negative 
emotions associated with deaths in the family. The negative correlation signifies 
that as age increases, psychosocial adjustment decreases. As medical science moves 
forward, so does the ability to delay or prevent SCD from ARVC. Older individuals 
may have memories of family members experiencing SCD before ARVC could be 
diagnosed or treated. Younger individuals may not experience as many deaths as 
older relatives due to advances made in the treatment of ARVC and may therefore 
score better on a scale designed to measure the negative experiences within the 
family. Second, there was a positive correlation between sex and the GTP scale. The 
GTP scale was designed to measure the importance an individual places on various 
aspects of preparing for genetic testing. At the data level, men were assigned a value 
of 1 and women were assigned a value of 2.  
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Table 13: ANOVA for each subscale of HD-GT 
 
  Sex Carrier/Non-Carrier Sex of transmitting 
parent 
Age in years 
 Adjusted 
r square 
Beta t Beta t Beta t Beta t 
IARVC 0.156 -0.180 -1.600 -0.082 -0.722 -0.197 -1.666 -0.313b -2.696 
GTP 0.048 0.259c 2.178 0.148 0.218 -0.062 -0.513 0.028 0.232 
FCGT -0.017 0.002 0.019 -0.174 -1.381 -0.010 -0.079 0.147 1.139 
WC 0.033 -0.155 -1.292 0.085 0.704 0.080 0.643 0.194 1.588 
SGTR 0.190 0.299b 2.752 -0.179 -1.632 -0.292b -2.589 0.009 0.080 
UR -0.038 0.052 0.425 0.010 0.083 -0.101 0.083 -0.055 -0.440 
TB -0.044 0.001 0.006 0.004 0.032 -0.008 -0.062 0.133 1.027 
CGL -0.001 0.205 1.668 -0.071 -0.578 -0.005 -0.037 0.113 0.902 
DI 0.057 0.210 1.722 -0.143 -1.162 0.023 0.182 0.003 0.021 
 
ap ≤ 0.001; b0.001 < p ≤ 0.01; c0.01 < p ≤ 0.05 
 
*beta values are standardized 
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Table 14: ANOVA for each subscale of PAHD 
 
  Sex Carrier/Non-Carrier Sex of transmitting 
parent 
Age in years 
 Adjusted 
r square 
Beta t Beta t Beta t Beta t 
BK -0.019 -0.105 -0.841 0.169 1.356 0.036 0.282 -0.002 -0.016 
FSARVC 0.073 0.124 1.060 -0.173 -1.467 -0.227 -1.872 0.212 1.773 
ap ≤ 0.001; b0.001 < p ≤ 0.01; c0.01 < p ≤ 0.05 
 
*beta values are standardized 
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The positive correlation signifies that women place more value on 
preparation than men. Third, there was a positive correlation between sex and the 
SGTR scale. The SGTR scale was intended to measure the importance an individual 
places on having social support when receiving test results. The positive correlation 
signifies that women place more importance on social support at this stage than do 
men. Fourth, and not previously studied in the literature, is a negative correlation 
between transmitting parent and the SGTR scale. At the data level, mothers were 
assigned a value of 1 and fathers a value of 2. The negative correlation signifies that 
those who inherited the ARVC gene from their mother score better on this scale. As 
ARVC affects men more severely, survey participants who inherited the gene from 
the paternal side likely experienced the death of his or her father at a young age and 
may not have a parent who has experienced the process as a source of guidance. 
Those who inherited the gene from the maternal side may have a living parent who 
has lived through the process and is able to act as a source of support when 
undergoing the testing process. 
Summary 
 This pilot study was designed to assess the validity and reliability of two 
surveys designed for LS for use in the ARVC population. Study findings support item 
level and scale level assumptions set forth in the literature. Most item-scale 
correlations fell within the ideal 0.40 to 0.70 range with few exceptions, and internal 
consistency of the scales was supported by alpha values at or near the 
recommended value of 0.70. Given the small sample size of this study, items below 
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recommended thresholds cannot be discounted and should be reassessed in a larger 
study.  
 Preliminary psychosocial analysis identified influences of age, sex, and 
transmitting parent, but did not demonstrate any differences in scores between 
carriers and non-carriers.  
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CHAPTER 5 
Discussion 
This chapter begins with a discussion of the testing of two psychometric 
testing tools: the HD-GT scale and the PAHD scale for use in the Newfoundland 
ARVC population. This is followed by a discussion of the resulting scores for each 
survey. 
Psychometric Properties 
Testing of both surveys was based on the work of Ware and Gandek (1998), 
whose validation process has been used in numerous psychometric testing studies 
including the validation of the HD-GT and PAHD scales for LS in the Newfoundland 
and Labrador population (LeDrew, 2009; Way et al., 2011). 
Target Population and Sample 
The target population of this study was individuals born at an a priori 50% 
risk for the TMEM43 mutation known to cause ARVC who had undergone direct 
mutation testing. The numbers of individuals whose mothers had the mutation and 
those whose fathers had the mutation responded in approximately equal numbers. 
Slightly more carriers than non-carriers responded. This may be because carriers 
perceived they had more to contribute to a research study about psychosocial 
impacts than non-carriers. The first symptom of ARVC is often SCD; as a result, the 
Newfoundland ARVC population has been very receptive to research designed to 
improve treatment of the condition. Those who are carriers of the mutation may 
have felt more inclined to participate in this study because the results may directly 
benefit themselves or their children/grandchildren. Significantly more women than 
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men participated in this study, which may be due to the nature of the condition itself. 
Since ARVC affects men earlier and more severely than it does women, women who 
are carriers tend to live much longer than men who are carriers and therefore the 
living ARVC population is more than 50% women. 
Subscale Structure 
 The finalized LS versions of both surveys were used to create the subscale 
structure for this study. Items that were ultimately removed in LS studies were also 
excluded here for future comparability of results.  
Data Quality and Item-Level Scaling Assumptions 
 Data quality is evaluated in terms of the amount of missing data, and the 
frequency distribution of response choices (Ware & Gandek, 1998) . A large amount 
of missing data, or missing data that seem systematic may be indicative of difficulty 
understanding particular items. Missing data in this study were minimal and 
random so we can conclude that there were no major comprehension issues with 
any particular item. As stated in a previous chapter, newly diagnosed families were 
excluded during recruitment, so individuals participating in the current study have 
had experience with ARVC and would therefore be familiar with any terminology 
specific to ARVC or genetics (e.g. carrier/non-carrier, inherited, generation, 
geneticist/genetic counsellor, ECG, Holter monitor).  
Quality data should also include the full range of response choices and the 
frequency of response choices for each item should be approximately equal with the 
exception of questions that are emotionally charged or identify uncommon states. 
Items with severely skewed frequency distributions all met the criteria for 
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exception. All items in the scales GTP, FCGT, and UR were severely skewed, but all 
represent uncommon states for the sample population. The GTP scale measured the 
importance individuals place on various aspects of preparing for genetic testing 
such as understanding the testing process, understanding one’s risk, and knowing if 
one has the mutation for children or grandchildren. Since all study participants have 
undergone genetic testing, they have already made the decision to be tested and 
therefore must consider testing to be an important part of living with the risk of 
ARVC. The FCGT scale measured the concern for family members who refuse genetic 
testing. Similarly, since all participants have undergone genetic testing, they would 
be the individuals within the family to encourage others to be tested.  It would be 
highly unusual for people to undergo genetic testing and to then claim that is it not 
important to them or to discourage other family members from being tested. Since 
low scores on both scales represent an uncommon state in the context of the target 
population, items within these scales are not required to have symmetrical 
frequency distributions. A low UR scale score also represents an uncommon state. 
The scale measures the extent of an individual’s belief that early detection of the 
condition and healthy living habits contribute to the management ARVC. It would be 
highly unusual for someone to opt for genetic testing and have the attitude that 
early detection is not beneficial. For this reason, the UR scale can be included in the 
survey despite skewed scores on all items.  
 At the item level, the standard deviation and mean for each item within a 
scale are assumed to be similar. This holds true for the majority of items with few 
exceptions. Items that did not meet the criteria were emotionally charged or items 
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that had expected answers but still represent an important element of its scale. 
According to Ware and Gandek, these are acceptable reasons for inclusion.  
Scale Level Assumptions 
 Three Likert scale assumptions were tested by determining item internal 
consistency and equality of item-scale correlations. The majority of items correlated 
to their respective scales with Pearson item-scale correlations at or above 0.40, the 
cut-off proposed by Ware and Gandek. A small number of items did not quite reach 
0.40; however, because these items did provide a unique piece of information and 
the small sample size in this study, these items were not discounted.  
 Item discriminant validity was also calculated to determine the strength of 
each item’s correlation with its own scale when compared to other scales. The 
majority of items received the recommended value of 2, meaning that the strength 
of the item’s correlation with its own scale was at least 2 standard errors greater 
than the item’s correlation with another scale. Most items that did not reach a value 
of 2 were the items with low internal consistency. Items with low internal 
consistency or those that correlate with two or more scale may fail the item 
discriminant validity test in a small sample but should not be discounted until the 
items are retested in a larger sample(Ware & Gandek, 1998) . 
Reliability and Validity 
 The Chronbach’s Alpha coefficient was used to determine scale internal 
consistency. Five of the nine scales for the HD-GT survey met the recommended cut-
off of 0.70 and the four scales that did not meet the cut-off were all above 0.60. 
Again, due to the small margin and the small sample size, retesting in a larger 
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population may result in an improvement of these values. Overall, internal 
consistency of each scale was higher than any one item-scale correlation, and 
correlations between scales were all relatively weak. Both scales in the PAHD survey 
exceeded the recommended cut-off. This supports the reliability and validity of both 
surveys in the ARVC population.  
Interpretation of Scores 
 Results from the HD-GT and PAHD align well with psychosocial literature 
surrounding ARVC and other genetic conditions, and offer some insight into internal 
conflicts individuals may face.  
 Low scores after reverse coding on the IARVC scale indicate that the 
experience of living in a family with ARVC has a substantial impact on the decision 
to undergo genetic testing. The IARVC scale measures the negative implications of 
living in a family with ARVC such as the loss of family members, the fear of losing 
family members in the future, and fear for one’s own future health. Low scores on 
this scale indicate these factors carried more weight in the decision to seek testing. 
Studies of various inherited conditions consistently conclude that individuals who 
have experienced the death of a family member or the onset of disease symptoms 
are more likely to opt for genetic testing(Armstrong et al., 2000; Cox, 2003; 
d'Agincourt-Canning, 2005; Etchegary, 2006; Etchegary et al., 2010; Kasparian et al., 
2009; Klitzman et al., 2007; Manuel & Brunger, 2014; McAllister, 2002; Norris et al., 
2009; Smith et al., 2002) . SCD can often be the first symptom of ARVC, so the onset 
of symptoms is less likely than the loss of family members to be a contributing 
factor. The lasting effects of losing a family member may also explain the negative 
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correlation between score on the IARVC scale and age. The negative correlation 
implies that older respondents scored lower on this scale, and a low score indicates 
that the experience of living in a family with ARVC weighs heavily on the decision to 
undergo testing.  
This subtype of ARVC was first found in Newfoundland families in the 1980s 
so some survey respondents would have memories of family members dying 
suddenly before ever hearing of ARVC. Many others would have experienced living 
at risk for ARVC prior to the availability of haplotype testing in 1998, when ARVC 
could only be diagnosed when an individual began showing symptoms. During this 
time period, SCD was unpredictable and relatively unpreventable so there would 
have been a great deal of uncertainty and worry surrounding ARVC risk. Once 
haplotype testing became available in 1998, it was possible to identify pre-
symptomatic individuals and take measures to prevent SCD through the use of 
implantable cardioverter defibrillators (ICDs) and medications. Younger survey 
respondents likely have fewer first-hand experiences with losing family members 
suddenly to ARVC as treatment options were more widely available. For this reason, 
younger individuals may be less influenced by the death of family members when 
making genetic testing decisions than their older family members.  
 The second subscale (GTP) measures the importance given to preparation 
when making a genetic testing decision. High scores on this subscale indicate that 
survey respondents believe it is important to know whether or not one has the gene 
and to be informed about the process. Three items dealing with the importance of 
knowing whether one has the gene had the highest scores within this scale. This is 
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consistent with the literature as the desire to define one’s own risk and risk for 
children is often cited as the primary motivation to undergo genetic testing (Aatre & 
Day, 2011; Claes et al., 2004; Clark et al., 2000; Esplen et al., 2007; Ormondroyd et al., 
2014) . This also corroborates the findings from qualitative research in the ARVC 
population that individuals feel a relational responsibility to other family members, 
particularly children and grandchildren to be tested (Etchegary et al., 2014; Manuel 
& Brunger, 2014) . In conditions where treatment is available, as is the case with 
ARVC, this motivation is amplified (Manuel & Brunger, 2014) . Also noteworthy is 
that females scored significantly higher on this scale. This may be due to the 
emotionally charged content dealing with the health of children and grandchildren. 
Since men tend to be affected at a younger age than women, male respondents may 
be less likely to have children or grandchildren of their own. The difference seen 
here between male and female scores may be confounded by the inherent age bias 
in this sample. 
 The third scale, FCGT, identifies challenges that families face when family 
members have differing opinions surrounding genetic testing. This scale also had 
particularly high scores, indicating that survey respondents felt it important for all 
family members to undergo testing and felt concern for family members who refuse 
testing. This theme was also present in the qualitative research as participants felt 
that it is a person’s duty to be tested and that testing should be sought whenever 
available (Manuel & Brunger, 2014) .  
 Moderate scores were seen in the fourth and fifth subscales, WC and SGTR. 
These scales deal with waiting for and receiving genetic testing results. A moderate 
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mean and relatively symmetrical frequency distributions for items within these 
scales indicate that individuals were not particularly concerned with the time 
between testing and receiving results and have different preferences for the way in 
which results are disclosed.  
One noteworthy result here was the impact of the sex of the transmitting 
parent on the importance an individual places on having social support when 
receiving test results. Those who inherited the mutation from their father scored 
worse on the SGTR scale. As ARVC affects men more severely, survey participants 
who inherited the gene from their father likely experienced their father’s death at a 
young age. Those who inherited the gene from their mother may not have lost their 
mother to the disease and she could have acted as their source of social support. 
Those who have a parent who has lived with ARVC who can guide them through the 
testing process would be more likely to assign a greater value to the social support 
received from their parent while receiving test results. Additionally, women scored 
significantly higher than men on this scale. This was expected as women tend to 
value social support during emotional events more so than men.  
 High scores on the UR scale indicate that the majority of the at-risk 
population has a good understanding of their ARVC risk and what that risk means. 
This may be due partly to selection bias as new families were excluded and all 
participants have undergone genetic testing. The majority of survey respondents 
have been living with the knowledge of their test results for some time and have had 
time to learn about the condition and what it means to be a carrier or non-carrier. 
This scale deals with the knowledge of screening and treatment options as well as 
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the influence of healthy living behaviors so anyone who has undergone testing 
would be well-informed on the topic.  
 Scores on the TB scale were moderate and variable. With high scores in the 
UR scale, implying a good understanding of the condition, the variable scores in this 
scale may be due to the perception of different patterns in different families. 
However, the majority of respondents agreed that men and women are affected 
differently, something that is a fact with this subtype of ARVC.  
 The final two subscales of the HD-GT survey, CGL and DI deal with 
communication issues within families. Both scales showed moderate and varying 
scores, indicating that families communicate differently about the genetic link and 
each family has unique issues. One item that is particularly variable is item A10.2 
that deals with difficulty informing young family members of ARVC risk. This 
particular item was split, with large numbers of respondents choosing one extreme 
or the other. This could indicate that families may need guidance or assistance from 
clinicians to inform younger family members of the ARVC risk.  
One item that had a particularly high mean score when compared to the other 
items in the scale was A10.10, which asks respondents about the importance of 
protecting the rights of others when disclosing risk. While most respondents place 
great importance on testing and encourage others to be tested, the majority of 
respondents answered strongly in favor of protecting the rights of others. Genetic 
testing can be a highly valuable tool, but the decision to be tested does not occur in 
isolation. Revealing one’s own result has the potential to implicate the result of 
another family member. This can be particularly troublesome when a family 
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member does not want to know their own result, where there may be a previously 
undisclosed adoption or question of paternity, or where disclosure of risk or test 
results to a child may have negative psychosocial effects. One female survey 
respondent expressed gratitude for not being informed of risk until adulthood as 
there was no immediate risk to her health if she were not told, and she was 
particularly athletic and her social circle in childhood and adolescence was rooted in 
sport. The decision may be more difficult for a parent in the case of male children, as 
withholding information about risk or test results may put the child’s life at risk.  
 Both BK and FSARVC scales within the PAHD survey had moderate and 
variable scores. One item, B1.8_R, in the BK scale had a mean significantly different 
than the other items in the scale. This item has to do with the worry for the future of 
young family members and had a particularly low score, meaning that respondents 
do indeed worry about young family members. This is expected as concern for other 
family members, particularly children, is a consistent theme across all hereditary 
conditions. Since ARVC can affect teens and young adults, the risk is more 
immediate than with many other hereditary conditions that may not appear until 
later in adulthood.  
 Item B2.6 also had a particularly low mean. This item has to do with the 
acceptance of one’s own future through caring for an affected family member. Since 
people affected by ARVC do not typically show symptoms and rarely show 
symptoms that require ongoing care from another person, individuals are not 
typically in caregiver roles for a family member unless it is for a condition other 
than ARVC. These surveys were developed for hereditary cancers where family 
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members may regularly act as caregivers for the condition under study. As this 
dynamic is relatively uncommon in ARVC, this item’s low mean is expected.  
Summary 
Based on the preliminary findings from this pilot, the HD-GT and PAHD 
Surveys were considered to be reliable and valid in an ARVC population, with the 
exception of a small number of items that require re-examination in a larger study. 
Items and subscales satisfied the assumptions set forth in an accepted method of 
survey validation. Items that did not satisfy the assumptions met the criteria for 
inclusion, and scales that did not meet cut-offs were very close to an acceptable 
value, warranting re-examination in a larger study. Overall, both surveys being 
studied show promise for clinical use in ARVC populations. 
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CHAPTER 6 
Limitations and Implications 
This chapter discusses the limitations, strengths, and implications of study 
findings. The first section examines the limitations and strengths of the study. The 
second section examines implications for healthcare providers at all levels as well as 
for new and current ARVC patients.  
Limitations and Strengths 
As the current study is a pilot, the small sample size limits the 
generalizability of the data. Most items that failed various stages of psychometric 
testing could were borderline and could not be discounted due to the small sample 
size. Rather, results of this study indicate that both scales have some merit in the 
ARVC population and warrant further testing in a larger sample to verify the 
conclusions.  The small sample size also limited the ability to analyze subgroups. 
Ability to analyze subgroups or other key variables was also limited by the 
dataset being used. While updated information is kept on file in clinic charts, the 
dataset used for this study is regularly updated. The dataset contains a great deal of 
missing or out of date information so some potentially clinically or socially 
significant variables were excluded as they were not readily available. Within the 
time constraints of this study, it was not possible to update the dataset from clinical 
charts.  
This pilot may also be somewhat limited by selection bias. Newly ascertained 
families were excluded from recruitment as it was thought that individuals who had 
been newly diagnosed had not had time to process their test results and that 
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participating in psychosocial research might cause additional distress. This may 
have resulted in skewed results in subscales related to knowledge of ARVC and the 
causative gene. Excluding newly ascertained families may also result in an 
overrepresentation of the long-term impact. While some individuals in the included 
families may be newly diagnosed, they would still be relatively familiar with ARVC 
through other family members.  
One of the strengths of this study is the ascertainment of the population. 
Individuals in the Newfoundland ARVC database are identified through pedigrees 
and then sought out by the genetics team. Unlike ARVC studies in populations 
outside Newfoundland, we have knowledge of all family members regardless of 
whether or not they have been to a genetics clinic. 
Another strength of this study is the alignment of quantitative results found 
here and qualitative results from previous studies within the same population. This 
indicates that both scales have the potential to accurately quantify emotions and 
attitudes toward genetic testing for ARVC. Another notable strength is the 
readability of both scales. Surveys were self-administered and the percentage of 
missing data was low, indicating that there were no major comprehension problems 
for any particular item.  
Implications 
Study findings have implications for both healthcare professionals and 
patients in terms of clinical management and education.  
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Clinical Management 
 Results of both scales have implications for any healthcare professional who 
works with ARVC patients on a regular basis including but not limited to family 
physicians, cardiologists, geneticists, genetic counsellors and other Cardiac Genetics 
clinic staff. In 2004, a Cardiac Genetics clinic was opened in St. John’s, NL for families 
at risk for ARVC. For individuals in ARVC families, visits to this clinic are often 
associated with very emotional stages of the genetic testing and treatment process: 
receiving information about the testing process, receiving genetic test results, 
receiving information about treatment options, check-ups or investigation following 
the onset of symptoms, etc. These tools may therefore provide healthcare providers 
within specialized clinics such as these with insight into areas of concern that are 
likely contributing to the emotional state of specific patients. Results of these 
surveys may provide clinicians with information about a patient’s level of 
understanding, attitudes toward various aspects of the testing process, and his or 
her specific concerns, which may influence the steps taken to guide the patient 
through the testing process and beyond. There may be a psychosocial effect 
highlighted by an individual’s survey results that had not been previously identified 
or was not expected. By receiving additional information, an individual’s circle of 
care may be able to provide anticipatory guidance throughout the testing process 
and subsequent treatment plan to reduce any negative psychosocial effects.  
 However, due to the sparse geography of the province of Newfoundland and 
Labrador and the location of specialized physicians, a large number of ARVC 
patients receive care primarily from family physicians. A large number of ARVC 
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patients live in rural areas where access to geneticists and cardiologists is extremely 
limited. Family physicians are often tasked with managing complex conditions such 
as ARVC, particularly when patients do not have easy access to specialized care. 
Having reliable psychometric tools may help family physicians better understand 
the specific needs of their ARVC patients so that appropriate care can be provided. 
Further studies may be able to relate scores obtained on these scales to 
standardized measures of coping or distress to guide clinicians.  
 Similarly, patients may directly benefit from the surveys as completing the 
surveys requires a great deal of self-reflection. Completing the surveys may bring up 
topics or emotions that an individual had not previously considered which may 
guide that person to seek out appropriate resources. For example, an individual may 
become more aware of tension between family members when asked about conflicts 
arising from disclosure issues, and seek out family counselling. These tools offer the 
option of patient-centered care, which in turn may improve the psychosocial well 
being of those affected. Scores on particular scales may identify specific problem 
areas for an individual and allow the health care provider administering the survey 
to suggest appropriate resources.  
 If common themes arise from larger scale use of these surveys, this may also 
help guide the formation of new psychosocial resources. For example, if a large 
number of family conflicts arise from disclosure issues, it may warrant the training 
of family counsellors with specialized knowledge of ARVC or the development of 
tools to assist families with communication about inherited risk.  
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Education 
Both surveys also have the potential to highlight educational needs for 
clinicians and patients. For clinicians who do not have a great deal of experience 
with ARVC, these survey tools may highlight the range of possible psychosocial 
effects. Since a large number of ARVC patients reside in rural areas, local healthcare 
providers may not fully understand the condition, much less the range of emotional 
issues patients may experience as a result. Utilization of these tools may raise 
awareness of possible psychosocial issues and result in better overall care. 
These tools may also be useful for clinicians by identifying gaps in patient 
knowledge, particularly for newly diagnosed individuals. This study excluded 
individuals in newly ascertained families however there several mid to low scores 
on items related to understanding ARVC and the genetic basis of the condition. 
When clinicians can identify misconceptions held by older families, it may help them 
avoid those same misconceptions in newer families. For example, if survey results 
show that individuals in older families do not understand their own risk for ARVC, 
clinicians may spend more time explaining the inheritance pattern to new patients 
so to maximize understanding of personal risk. These surveys may also be used to 
identify gaps in understanding for individual patients. Newly diagnosed individuals 
receive a great deal of information in a short period of time, so completion of the 
survey may highlight information that was not initially understood or was not 
received. Individuals who were tested at a young age or many years ago may also 
have missed or forgotten key information. By identifying these gaps in 
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understanding, healthcare providers may be able to offer more education on specific 
topics.    
Conclusion 
 This pilot study examined two psychometric testing tools for use in the 
Newfoundland ARVC population. This was the first quantitative study of 
psychosocial adjustment in an ARVC population.  
 Preliminary findings indicate potential for both survey tools to be used in the 
ARVC population as the majority of items and subscales were found to be valid and 
reliable. Further testing in a larger study is required to confirm these results and 
polish the surveys for clinical use. Further psychometric testing may be able to 
identify items that are unnecessary resulting in shorter surveys and reduced patient 
burden. 
 Findings from this study also highlighted a small number of clinical variables 
that may have an affect on overall psychosocial impact. Statistically significant 
correlations aligned with current qualitative psychosocial research, further 
supporting the future usefulness of the two survey tools.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
References 
Aatre, R. D., & Day, S. M. (2011). Psychological issues in genetic testing for inherited 
cardiovascular diseases. Circulation: Cardiovascular Genetics, 4(1), 81-90. 
doi:10.1161/CIRCGENETICS.110.957365 
Ahmad, F., Li, D., Karibe, A., Gonzalez, O., Tapscott, T., Hill, R., . . . Roberts, R. (1998). 
Localization of a gene responsible for arrhythmogenic right ventricular 
dysplasia to chromosome 3p23. Circulation, 98(25), 2791-2795. 
doi:10.1161/01.CIR.98.25.2791 
Appleton, S., Fry, A., Rees, G., Rush, R., & Cull, A. (2000). Psychosocial effects of living 
with an increased risk of breast cancer: An exploratory study using telephone 
focus groups. Psycho-Oncology, 9(6), 511-521. doi:10.1002/1099-
1611(200011/12)9:6<511::AID-PON469>3.0.CO;2-E [pii] 
Armstrong, K., Calzone, K., Stopfer, J., Fitzgerald, G., Coyne, J., & Weber, B. (2000). 
Factors associated with decisions about clinical BRCA1/2 testing. Cancer 
Epidemiology, Biomarkers & Prevention : A Publication of the American 
Association for Cancer Research, Cosponsored by the American Society of 
Preventive Oncology, 9(11), 1251-1254.  
Bakos, A. D., Hutson, S. P., Loud, J. T., Peters, J. A., Giusti, R. M., & Greene, M. H. (2008). 
BRCA mutation-negative women from hereditary breast and ovarian cancer 
families: A qualitative study of the BRCA-negative experience. Health 
 91 
Expectations : An International Journal of Public Participation in Health Care and 
Health Policy, 11(3), 220-231. doi:10.1111/j.1369-7625.2008.00494.x [doi] 
Baumann, S. L. (2006). Family systems genetic illness model-- breast cancer. Clinical 
Journal of Oncology Nursing, 10(3), 377.  
Bjorvatn, C., Eide, G. E., Hanestad, B. R., & Havik, O. E. (2008). Anxiety and depression 
among subjects attending genetic counseling for hereditary cancer. Patient 
Education and Counseling, 71(2), 234-243. doi:10.1016/j.pec.2008.01.008 [doi] 
Bonis, P. A., Trikalinos, T. A., Chung, M., Chew, P., Ip, S., DeVine, D. A., & Lau, J. (2007). 
Hereditary nonpolyposis colorectal cancer: Diagnostic strategies and their 
implications. Evidence Report/Technology Assessment, (150), 1-180.  
Botkin, J. R., Belmont, J. W., Berg, J. S., Berkman, B. E., Bombard, Y., Holm, I. A., . . . 
Mcinerney, J. D. (2015). Points to consider: Ethical, legal, and psychosocial 
implications of genetic testing in children and adolescents. The American 
Journal of Human Genetics, doi:10.1016/j.ajhg.2015.05.022 
Bowen, D. J., Bourcier, E., Press, N., Lewis, F. M., & Burke, W. (2004). Effects of 
individual and family functioning on interest in genetic testing. Public Health 
Genomics, 7(1), 25-32. Retrieved from 
http://www.karger.com/DOI/10.1159/000080301 
 92 
Broadstock, M., Michie, S., & Marteau, T. (2000). Psychological consequences of 
predictive genetic testing: A systematic review. European Journal of Human 
Genetics, 8(10), 731. doi:10.1038/sj.ejhg.5200532 
Carlsson, C., & Nilbert, M. (2007). Living with hereditary non-polyposis colorectal 
cancer; experiences from and impact of genetic testing. Journal of Genetic 
Counseling, 16(6), 811-820. doi:10.1007/s10897-007-9117-0 [doi] 
Carroll, D. L., Hamilton, G. A., & McGovern, B. A. (1999). Changes in health status and 
quality of life and the impact of uncertainty in patients who survive life-
threatening arrhythmias. Heart & Lung - the Journal of Acute and Critical Care, 
28(4), 251-260. doi:10.1016/S0147-9563(99)70071-3 
Christensen, A. H., Andersen, C. B., Tybjaerg-Hansen, A., Haunso, S., & Svendsen, J. H. 
(2011). Mutation analysis and evaluation of the cardiac localization of TMEM43 
in arrhythmogenic right ventricular cardiomyopathy. Clinical Genetics, 80(3), 
256-264. doi:10.1111/j.1399-0004.2011.01623.x 
Claes, E., Denayer, L., Evers-Kiebooms, G., Boogaerts, A., & Legius, E. (2004). 
Predictive testing for hereditary non-polyposis colorectal cancer: Motivation, 
illness representations and short-term psychological impact. Patient Education 
and Counseling, 55(2), 265-274. doi:S0738399103003045 [pii] 
Clark, S., Bluman, L., Borstelmann, N., Regan, K., Winer, E., Rimer, B., & Skinner, C. 
(2000). Patient motivation, satisfaction, and coping in genetic counseling and 
 93 
testing for BRCA1 and BRCA2. Journal of Genetic Counseling, 9(3), 219-235. 
doi:10.1023/A:1009463905057 
Codori, A. M., Petersen, G. M., Boyd, P. A., Brandt, J., & Giardiello, F. M. (1996). Genetic 
testing for cancer in children. short-term psychological effect. Archives of 
Pediatrics & Adolescent Medicine, 150(11), 1131-1138.  
Codori, A. M., Zawacki, K. L., Petersen, G. M., Miglioretti, D. L., Bacon, J. A., Trimbath, J. 
D., . . . Giardiello, F. M. (2003). Genetic testing for hereditary colorectal cancer in 
children: Long-term psychological effects. American Journal of Medical 
Genetics.Part A, 116A(2), 117-128. doi:10.1002/ajmg.a.10926 [doi] 
Collins, V. R., Meiser, B., Ukoumunne, O. C., Gaff, C., St John, D. J., & Halliday, J. L. 
(2007). The impact of predictive genetic testing for hereditary nonpolyposis 
colorectal cancer: Three years after testing. Genetics in Medicine : Official Journal 
of the American College of Medical Genetics, 9(5), 290.  
Cox, S. (2003). Stories in decisions: How at-risk individuals decide to request 
predictive testing for huntington disease. Qualitative Sociology, 26(2), 257-280. 
doi:10.1023/A:1022971113683 
Croyle, R. T., Smith, K. R., Botkin, J. R., Baty, B., & Nash, J. (1997). Psychological 
responses to BRCA1 mutation testing: Preliminary findings. Health Psychology, 
16(1), 63-72. doi:10.1037/0278-6133.16.1.63 
 94 
d'Agincourt-Canning, L. (2005). The effect of experiential knowledge on 
construction of risk perception in hereditary breast/ovarian cancer. Journal of 
Genetic Counseling, 14(1), 55-69. doi:10.1007/s10897-005-1500-0 [doi] 
d'Agincourt-Canning, L. (2006). A gift or a yoke? women's and men's responses to 
genetic risk information from BRCA1 and BRCA2 testing. Clinical Genetics, 70(6), 
462-472. doi:CGE720 [pii] 
Decruyenaere, M., Evers-Kiebooms, G., Boogaerts, A., Cloostermans, T., Cassiman, J. J., 
Demyttenaere, K., . . . Van den Berghe, H. (1997). Non-participation in predictive 
testing for huntington's disease: Individual decision-making, personality and 
avoidant behaviour in the family. European Journal of Human Genetics : EJHG, 
5(6), 351-363.  
Decruyenaere, M., Evers-Kiebooms, G., Cloostermans, T., Boogaerts, A., 
Demyttenaere, K., Dom, R., & Fryns, J. P. (2003). Psychological distress in the 5-
year period after predictive testing for huntington's disease. European Journal 
of Human Genetics : EJHG, 11(1), 30-38. doi:10.1038/sj.ejhg.5200913 [doi] 
den Heijer, M., Seynaeve, C., Vanheusden, K., Duivenvoorden, H. J., Bartels, C. C. M., 
Menke-Pluymers, M. B. E., & Tibben, A. (2011). Psychological distress in women 
at risk for hereditary breast cancer: The role of family communication and 
perceived social support. Psycho-Oncology, 20(12), 1317-1323. 
doi:10.1002/pon.1850 
 95 
Di Prospero, L. S., Seminsky, M., Honeyford, J., Doan, B., Franssen, E., Meschino, W., . . . 
Warner, E. (2001). Psychosocial issues following a positive result of genetic 
testing for BRCA1 and BRCA2 mutations: Findings from a focus group and a 
needs-assessment survey. CMAJ : Canadian Medical Association Journal = Journal 
De L'Association Medicale Canadienne, 164(7), 1005-1009.  
Djurdjinovic, L. (1998). Psychosocial counseling. In D. L. Baker, J. L. Schuette & W. R. 
Uhlmann (Eds.), A guide to genetic counselling (pp. 127-170). New York, NY: 
Wiley-Liss. 
Douma, K. F., Aaronson, N. K., Vasen, H. F., Gerritsma, M. A., Gundy, C. M., Janssen, E. 
P., . . . Bleiker, E. M. (2010). Psychological distress and use of psychosocial 
support in familial adenomatous polyposis. Psycho-Oncology, 19(3), 289-298. 
doi:10.1002/pon.1570 [doi] 
Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., & Delatycki, M. B. 
(2008). "You're one of us now": Young people describe their experiences of 
predictive genetic testing for huntington disease (HD) and familial 
adenomatous polyposis (FAP). American Journal of Medical Genetics.Part C, 
Seminars in Medical Genetics, 148C(1), 47-55. doi:10.1002/ajmg.c.30158 [doi] 
Eijzenga, W., Hahn, D., Aaronson, N., Kluijt, I., & Bleiker, E. (2014). Specific 
psychosocial issues of individuals undergoing genetic counseling for cancer – A 
literature review. Journal of Genetic Counseling, 23(2), 133-146. 
doi:10.1007/s10897-013-9649-4 
 96 
Erskine, K. E., Hidayatallah, N. Z., Walsh, C. A., McDonald, T. V., Cohen, L., Marion, R. 
W., & Dolan, S. M. (2014). Motivation to pursue genetic testing in individuals 
with a personal or family history of cardiac events or sudden cardiac death. 
Journal of Genetic Counseling, 23(5), 849-859. doi:10.1007/s10897-014-9707-6 
Esplen, M. J., Madlensky, L., Aronson, M., Rothenmund, H., Gallinger, S., Butler, K., . . . 
McLaughlin, J. (2007). Colorectal cancer survivors undergoing genetic testing 
for hereditary non-polyposis colorectal cancer: Motivational factors and 
psychosocial functioning. Clinical Genetics, 72(5), 394-401. doi:CGE893 [pii] 
Etchegary, H. (2006). Genetic testing for huntington's disease: How is the decision 
taken? Genetic Testing, 10(1), 60-67. doi:10.1089/gte.2006.10.60 [doi] 
Etchegary, H., Pullman, D., Simmonds, C., Young, T. L., & Hodgkinson, K. (2014). 'It 
had to be done': Genetic testing decisions for arrhythmogenic right ventricular 
cardiomyopathy. Clinical Genetics, doi:10.1111/cge.12513; 10.1111/cge.12513 
Etchegary, H., Lemyre, L., & Wilson, B. (2010). Bringing the social into genetics: The 
psychosocial genetics risk assessment and management framework (PG-RAM). 
Current Psychology, 29(3), 171-187. doi:10.1007/s12144-010-9085-7 
Foster, C., Watson, M., Eeles, R., Eccles, D., Ashley, S., Davidson, R., . . . Psychosocial 
Study Collaborators. (2007). Predictive genetic testing for BRCA1/2 in a UK 
clinical cohort: Three-year follow-up. British Journal of Cancer, 96(5), 718-724. 
doi:6603610 [pii] 
 97 
Friedmann, E., Thomas, S. A., Inguito, P., Kao, C. W., Metcalf, M., Kelley, F. J., & Gottlieb, 
S. S. (2006). Quality of life and psychological status of patients with implantable 
cardioverter defibrillators. Journal of Interventional Cardiac Electrophysiology, 
17(1), 65-72. doi:10.1007/s10840-006-9053-1 
Frost, C. J., Venne, V., Cunningham, D., & Gerritsen-McKane, R. (2004). Decision 
making with uncertain information: Learning from women in a high risk breast 
cancer clinic. Journal of Genetic Counseling, 13(3), 221-236. doi:486127 [pii] 
Hallowell, N. (2006). Risky relations. family, kinship and the new genetics by 
featherstone, K., atkinson, P., bharadwaj, A. and clarke, A. Sociology of Health & 
Illness, 28(7), 990-992. doi:10.1111/j.1467-9566.2006.522_2.x 
Hamang, A., Eide, G. E., Nordin, K., Rokne, B., Bjorvatn, C., & Oyen, N. (2010). Health 
status in patients at risk of inherited arrhythmias and sudden unexpected death 
compared to the general population. BMC Medical Genetics, 11, 27-2350-11-27. 
doi:10.1186/1471-2350-11-27 [doi] 
Hamann, H. A., Smith, T. W., Smith, K. R., Croyle, R. T., Ruiz, J. M., Kircher, J. C., & 
Botkin, J. R. (2008). Interpersonal responses among sibling dyads tested for 
BRCA1/BRCA2 gene mutations. Health Psychology, 27(1), 100-109. 
doi:10.1037/0278-6133.27.1.100 
Hamilton, J. G., Lobel, M., & Moyer, A. (2009). Emotional distress following genetic 
testing for hereditary breast and ovarian cancer: A meta- analytic review. 
Health Psychology, 28(4), 510-518. doi:10.1037/a0014778 
 98 
Hamilton, R., & Hurley, K. E. (2010). Conditions and consequences of a BRCA 
mutation in young, single women of childbearing age. Oncology Nursing Forum, 
37(5), 627-634. doi:10.1188/10.ONF.627-634 [doi] 
Heshka, J. T., Palleschi, C., Howley, H., Wilson, B., & Wells, P. S. (2008). A systematic 
review of perceived risks, psychological and behavioral impacts of genetic 
testing. Genetics in Medicine : Official Journal of the American College of Medical 
Genetics, 10(1), 19-32. doi:10.1097/GIM.0b013e31815f524f [doi] 
Hodgkinson, K. A., Connors, S. P., Merner, N., Haywood, A., Young, T., McKenna, W. 
J., . . . Parfrey, P. S. (2013). The natural history of a genetic subtype of 
arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L 
mutation in TMEM43. Clinical Genetics, 83(4), 321-331. doi:10.1111/j.1399-
0004.2012.01919.x 
Hodgkinson, K. A., Parfrey, P. S., Bassett, A. S., Kupprion, C., Drenckhahn, J., Norman, 
M. W., . . . Connors, S. P. (2005). The impact of implantable cardioverter- 
defibrillator therapy on survival in autosomal-dominant arrhythmogenic right 
ventricular cardiomyopathy (ARVD5). Journal of the American College of 
Cardiology, 45(3), 400-408. doi:10.1016/j.jacc.2004.08.068 
Hodgkinson, K., Dicks, E., Connors, S., Young, T., Parfrey, P., & Pullman, D. (2009). 
Translation of research discoveries to clinical care in arrhythmogenic right 
ventricular cardiomyopathy in newfoundland and labrador: Lessons for health 
 99 
policy in genetic disease. Genetics in Medicine : Official Journal of the American 
College of Medical Genetics, 11(12), 859.  
Hodgkinson, K., & Pullman, D. (2010). Duty to warn and genetic disease. Canadian 
Journal of Cardiovascular Nursing = Journal Canadien En Soins Infirmiers Cardio-
Vasculaires, 20(1), 12.  
Jackson, H., Huisman, L., Sanatani, S., & Arbour, L. T. (2011). Long QT syndrome. 
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale 
Canadienne, 183(11), 1272. doi:10.1503/cmaj.100138 
Kasparian, N. A., Meiser, B., Butow, P. N., Simpson, J. M., & Mann, G. J. (2008). 
Predictors of psychological distress among individuals with a strong family 
history of malignant melanoma. Clinical Genetics, 73(2), 121-131. 
doi:10.1111/j.1399-0004.2007.00949.x [doi] 
Kasparian, N. A., Meiser, B., Butow, P. N., Simpson, J. M., & Mann, G. J. (2009). Genetic 
testing for melanoma risk: A prospective cohort study of uptake and outcomes 
among australian families. Genetics in Medicine : Official Journal of the American 
College of Medical Genetics, 11(4), 265. doi:10.1097/GIM.0b013e3181993175 
Keller, M., Jost, R., Haunstetter, C. M., Sattel, H., Schroeter, C., Bertsch, U., . . . Brechtel, 
A. (2008). Psychosocial outcome following genetic risk counselling for familial 
colorectal cancer. A comparison of affected patients and family members. 
Clinical Genetics, 74(5), 414-424. doi:10.1111/j.1399-0004.2008.01089.x [doi] 
 100 
Klitzman, R., Thorne, D., Williamson, J., Chung, W., & Marder, K. (2007). Disclosures 
of huntington disease risk within families: Patterns of decision-making and 
implications. American Journal of Medical Genetics.Part A, 143A(16), 1835-1849. 
doi:10.1002/ajmg.a.31864 [doi] 
Kopciuk, K. A., Choi, Y., Parkhomenko, E., Parfrey, P., Mclaughlin, J., Green, J., & 
Briollais, L. (2009). Penetrance of HNPCC-related cancers in a retrolective 
cohort of 12 large newfoundland families carrying a MSH2 founder mutation: 
An evaluation using modified segregation models. Hereditary Cancer in Clinical 
Practice, 7(1), 16. doi:10.1186/1897-4287-7-16 
Lammens, C. R., Aaronson, N. K., Wagner, A., Sijmons, R. H., Ausems, M. G., Vriends, A. 
H., . . . Bleiker, E. M. (2010). Genetic testing in li-fraumeni syndrome: Uptake and 
psychosocial consequences. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, 28(18), 3008-3014. 
doi:10.1200/JCO.2009.27.2112 [doi] 
Lapointe, J., Bouchard, K., Patenaude, A. F., Maunsell, E., Simard, J., & Dorval, M. 
(2012). Incidence and predictors of positive and negative effects of BRCA1/2 
genetic testing on familial relationships: A 3-year follow-up study. Genetics in 
Medicine : Official Journal of the American College of Medical Genetics, 14(1), 60-
68. doi:10.1038/gim.0b013e3182310a7f [doi] 
Lapointe, J., Dorval, M., Noguès, C., Fabre, R., Julian-Reynier, C., & GENEPSO Cohort. 
(2013). Is the psychological impact of genetic testing moderated by support and 
 101 
sharing of test results to family and friends? Familial Cancer, 12(4), 601. 
doi:10.1007/s10689-013-9621-3 
LeDrew, H. (2009). Psychometric testing of a scale designed to monitor the 
psychosocial and behavioral impact of genetic testing for hereditary nonpolyposis 
colorectal cancer (HNPCC): A pilot study. (Unpublished Masters). Memorial 
University of Newfoundland, Newfoundland. 
Lerman, C., Croyle, R. T., Tercyak, K. P., & Hamann, H. (2002). Genetic testing: 
Psychological aspects and implications. Journal of Consulting and Clinical 
Psychology, 70(3), 784-797. doi:10.1037/0022-006X.70.3.784 
Likert, R. (1932). A technique for the measurement of attitudes. Archives of 
Psychology, 22 140, 55.  
Lim, J., Macluran, M., Price, M., Bennett, B., Butow, P., & kConFab, P. G. (2004). Short- 
and long- term impact of receiving genetic mutation results in women at 
increased risk for hereditary breast cancer. Journal of Genetic Counseling, 13(2), 
115-133. doi:10.1023/B:JOGC.0000018822.56297.a6 
Lodder, E. M., & Bezzina, C. R. (2013). Arrhythmogenic right ventricular 
cardiomyopathy: Growing evidence for complex inheritance. 
Circulation.Cardiovascular Genetics, 6(6), 525-527. 
doi:10.1161/CIRCGENETICS.113.000367 [doi] 
 102 
Manuel, A., & Brunger, F. (2014). Making the decision to participate in predictive 
genetic testing for arrhythmogenic right ventricular cardiomyopathy. Journal of 
Genetic Counseling, 23(6), 1045-1055. doi:10.1007/s10897-014-9733-4 
Maron, B. J., & Maron, M. S. (2013). Hypertrophic cardiomyopathy. The Lancet, 
381(9862), 242-255. doi:http://dx.doi.org.qe2a-proxy.mun.ca/10.1016/S0140-
6736(12)60397-3 
McAllister, M. (2002). Predictive genetic testing and beyond: A theory of 
engagement. Journal of Health Psychology, 7(5), 491-508. 
doi:10.1177/1359105302007005628 [doi] 
McKenna, W. J., Thiene, G., Nava, A., Fontaliran, F., Blomstrom-Lundqvist, C., 
Fontaine, G., & Camerini, F. (1994). Diagnosis of arrhythmogenic right 
ventricular dysplasia/cardiomyopathy. task force of the working group 
myocardial and pericardial disease of the european society of cardiology and of 
the scientific council on cardiomyopathies of the international society and 
federation of cardiology. Heart, 71(3), 215-218. doi:10.1136/hrt.71.3.215 
Mellon, S., Gold, R., Janisse, J., Cichon, M., Tainsky, M. A., Simon, M. S., & Korczak, J. 
(2008). Risk perception and cancer worries in families at increased risk of 
familial breast/ovarian cancer. Psycho-Oncology, 17(8), 756-766. 
doi:10.1002/pon.1370 [doi] 
Merner, N. D., Hodgkinson, K. A., Haywood, A. F. M., Connors, S., French, V. M., 
Drenckhahn, J., . . . Young, T. (2008). Arrhythmogenic right ventricular 
 103 
cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused 
by a missense mutation in the TMEM43 gene. The American Journal of Human 
Genetics, 82(4), 809-821. doi:10.1016/j.ajhg.2008.01.010 
Michie, S., Bobrow, M., & Marteau, T. M. (2001). Predictive genetic testing in children 
and adults: A study of emotional impact. Journal of Medical Genetics, 38(8), 519-
526.  
Murray, B. (2012). Arrhythmogenic right ventricular dysplasia/cardiomyopathy 
(ARVD/C): A review of molecular and clinical literature. Journal of Genetic 
Counseling, 21(4), 494-504. doi:10.1007/s10897-012-9497-7 
Norris, J., Spelic, S. S., Snyder, C., & Tinley, S. (2009). Five families living with 
hereditary breast and ovarian cancer risk. Clinical Journal of Oncology Nursing, 
13(1), 73-80. doi:10.1188/09.CJON.73-80 [doi] 
Nunally, J., & Bernstein, I. (1994). Psychometric theory, 3rd edition. New York: 
Mcgraw-Hill,  
Ormondroyd, E., Oates, S., Parker, M., Blair, E., & Watkins, H. (2014). Pre-
symptomatic genetic testing for inherited cardiac conditions: A qualitative 
exploration of psychosocial and ethical implications. European Journal of 
Human Genetics : EJHG, 22(1), 88. doi:10.1038/ejhg.2013.81 
Peterson, S. K., Watts, B. G., Koehly, L. M., Vernon, S. W., Baile, W. F., Kohlmann, W. K., 
& Gritz, E. R. (2003). How families communicate about HNPCC genetic testing: 
 104 
Findings from a qualitative study. American Journal of Medical Genetics Part C: 
Seminars in Medical Genetics, 119(1), 78-86. doi:10.1002/ajmg.c.10010 
Pullman, D., & Hodgkinson, K. (2006). Genetic knowledge and moral responsibility: 
Ambiguity at the interface of genetic research and clinical practice. Clinical 
Genetics, 69(3), 199-203. doi:10.1111/j.1399-0004.2006.00581.x 
Rainville, I., & Rana, H. (2014). Next-generation sequencing for inherited breast 
cancer risk: Counseling through the complexity. Current Oncology Reports, 16(3), 
1-11. doi:10.1007/s11912-013-0371-z 
Rew, L. (2010). Systematic review of psychosocial benefits and harms of genetic 
testing. Issues in Mental Health Nursing, 31(10), 631-645. 
doi:10.3109/01612840.2010.510618 
Rew, L., Mackert, M., & Bonevac, D. (2009). A systematic review of literature about 
the genetic testing of adolescents. Journal for Specialists in Pediatric Nursing, 
14(4), 284-294. doi:10.1111/j.1744-6155.2009.00210.x 
Satia, J. A., McRitchie, S., Kupper, L. L., & Halbert, C. H. (2006). Genetic testing for 
colon cancer among african-americans in north carolina. Preventive Medicine, 
42(1), 51-59. doi:http://dx.doi.org/10.1016/j.ypmed.2005.10.004 
Schlich-Bakker, K. J., Warlam-Rodenhuis, C. C., van Echtelt, J., van den Bout, J., 
Ausems, M. G., & ten Kroode, H. F. (2006). Short term psychological distress in 
patients actively approached for genetic counselling after diagnosis of breast 
 105 
cancer. European Journal of Cancer (Oxford, England : 1990), 42(16), 2722-2728. 
doi:S0959-8049(06)00561-2 [pii] 
Schwartz, M. D., Peshkin, B. N., Hughes, C., Main, D., Isaacs, C., & Lerman, C. (2002). 
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-
based sample. Journal of Clinical Oncology : Official Journal of the American 
Society of Clinical Oncology, 20(2), 514-520.  
Sen-Chowdhry, S., Syrris, P., & McKenna, W. J. (2005). Genetics of right ventricular 
cardiomyopathy. Journal of Cardiovascular Electrophysiology, 16(8), 927-935. 
doi:10.1111/j.1540-8167.2005.40842.x 
Smart, R. V., Yu, B., Le, H., French, J. A., Richmond, D. R., Jeremy, R. W., . . . Trent, R. J. 
(1996). DNA testing in familial hypertrophic cardiomyopathy: Clinical and 
laboratory implications. Clinical Genetics, 50(4), 169.  
Smets, E. M., Stam, M. M., Meulenkamp, T. M., van Langen, I. M., Wilde, A. A., Wiegman, 
A., . . . Tibben, A. (2008). Health-related quality of life of children with a positive 
carrier status for inherited cardiovascular diseases. American Journal of Medical 
Genetics.Part A, 146A(6), 700-707. doi:10.1002/ajmg.a.32218 [doi] 
Smith, J. A., Michie, S., Stephenson, M., & Quarrell, O. (2002). Risk perception and 
decision-making processes in candidates for genetic testing for huntington's 
disease: An interpretative phenomenological analysis. Journal of Health 
Psychology, 7(2), 131-144. doi:10.1177/1359105302007002398 [doi] 
 106 
Te Riele, A. S., Tandri, H., & Bluemke, D. A. (2014). Arrhythmogenic right ventricular 
cardiomyopathy (ARVC): Cardiovascular magnetic resonance update. Journal of 
Cardiovascular Magnetic Resonance : Official Journal of the Society for 
Cardiovascular Magnetic Resonance, 16(1), 50-50. doi:10.1186/s12968-014-
0050-8 
Towbin, J. A. (2008). Arrhythmogenic right ventricular cardiomyopathy: A paradigm 
of overlapping disorders. Annals of Noninvasive Electrocardiology, 13(4), 325-
326. doi:10.1111/j.1542-474X.2008.00241.x 
Turner-Cobb, J. M., Bloor, L. E., Whittemore, A. S., West, D., & Spiegel, D. (2006). 
Disengagement and social support moderate distress among women with a 
family history of breast cancer. The Breast Journal, 12(1), 7-15. doi:TBJ178 [pii] 
van Oostrom, I., Meijers-Heijboer, H., Duivenvoorden, H. J., Brocker-Vriends, A. H., 
van Asperen, C. J., Sijmons, R. H., . . . Tibben, A. (2007). Family system 
characteristics and psychological adjustment to cancer susceptibility genetic 
testing: A prospective study. Clinical Genetics, 71(1), 35-42. doi:CGE731 [pii] 
Ventura, M. T., Napolitano, S., Buquicchio, R., Cecere, R., & Arsieni, A. (2012). An 
approach to urticaria in the elderly patients. Immunopharmacology and 
Immunotoxicology, 34(3), 530-533. doi:10.3109/08923973.2011.631549 
Vincent, M.,G.M. (1998). THE MOLECULAR GENETICS OF THE LONG QT SYNDROME: 
GENES CAUSING FAINTING AND SUDDEN DEATH 
doi:10.1146/annurev.med.49.1.263 
 107 
Ware, J. E., Brook, R., Davies-Avery, A., Williams, K., Stewart, A., & Rogers, W. (1980). 
Model of health and methodology. Santa Monica, CA: RAND Corporation. 
Ware, J. E., & Gandek, B. (1998). Methods for testing data quality, scaling 
assumptions, and reliability. Journal of Clinical Epidemiology, 51(11), 945-952. 
doi:10.1016/S0895-4356(98)00085-7 
Watkins, K. E., Way, C. Y., Gregory, D. M., LeDrew, H. M., Ludlow, V. C., Esplen, M. J., 
Parfrey, P. S. (2013). Development and preliminary testing of the psychosocial 
adjustment to hereditary diseases scale. BMC Psychology, 1(1), 7-7. 
doi:10.1186/2050-7283-1-7 
Way, C., Watkins, K., LeDrew, H., Ludlow, V., Esplen, M., Gregory, D., & Parfrey, P. 
(2011). Development and testing of the hereditary diseases and genetic testing 
(HD-GT) scale. Hereditary Cancer in Clinical Practice, 9(1) 
  
 
 
 
 
 
 
 
 
 
 108 
APPENDIX A 
GE3LS Research Program Structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GE3LS Program - Sudden Cardiac Death in Newfoundland and Labrador 
Phase 1 
Qualitative 
interviews study 
with known ARVC 
families with the 
purpose of 
identifying 
potential 
psychosocial 
impacts 
Phase 2 
Population 
sampling sub-study 
with the purpose of 
identifying 
unknown 
individuals at risk 
for ARVC 
Phase 3 
Quantitative 
exploration of 
psychosocial 
impacts of ARVC 
with known 
families 
Phase 4 
Development of 
educational tools 
for primary care 
physicians in the 
province. 
Etchegary, H., Pullman, D., Simmonds, C., Young, 
TL., & Hodgkinson, K. (2015). It had to be done. 
Genetic testing decisions for ARVC. Clinical 
Genetics 88:344-351 
 
Etchegary, H., Enright, G., Audas, R., Pullman, D., & 
Hodgkinson, K. (2015). Perceived economic 
burden association with an inherited 
cardiomyopathy – a qualitative inquiry with 
families affected by ARVC. Genetics in Medicine. 
Oct 29. Doi: 10.1038/gim.2015.132. [Epub ahead 
of print] 
80 individuals with family history of heart 
disease underwent genetic testing for ARVC. 
All tested negative.  
 
Completion of 4 validated, psychosocial 
surveys. Team will explore whether 
population sampling methods associated with 
increased distress. 
Tools will be designed to assist clinicians 
recognize red flags for ARVC patients and 
refer patients appropriately for cardiac 
genetics workup. 
Two graduate student projects: 
1. Economic impact of ARVC – ecomonic 
model constructed, highlighting areas of 
psychosocial impact.  
 
2. Psychosocial impact of ARVC – a 
quantitative assessment. Current study. 
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Dr. T-L Young, Dr. B. Fernandez, Dr. 
K. Hodgkinson, Dr. S Connors, and Dr. 
H Etchegary 
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Hereditary Disease and Genetic Testing Survey 
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Hereditary Diseases and Genetic Testing (HD-GT) Scale 
(ARVC Version) 
 
 
 
 
 
The HD-GT Scale has 10 sections with a total of 63 questions.  
 
Each section has several statements that we would like for you to rate 
from 0 (Not at all) to 4 (Extremely).  
 
Please circle the answer which best applies to you for all of the 
statements in each section. 
 
Thank you 
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A1: We are interested in the degree to which a family history of early 
sudden cardiac death caused by the ARVC gene influences a person’s 
decision to have genetic testing. 
 
Using the scale given, you are asked to rate how important each statement 
was in helping you to decide to have genetic testing. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
 
1. It seemed like a lot of family members were 
dying suddenly of cardiac problems more often 
and at a younger age than in other families. 
2. I have many memories of close family 
members dying suddenly at a young age. 
3. The presence of so much early sudden 
cardiac death in the family was hard to accept, 
and I wanted to know why. 
4.  It was scary to see the same pattern of early 
sudden cardiac death showing up in every 
generation of my family. 
5. It was so draining to lose close relatives to 
early sudden cardiac death that every time the 
phone rang I wondered who was sick this time. 
6. With so much suffering and early sudden 
cardiac deaths, I was worried about my own 
health and death. 
7. What worried me was that even when a 
family member seemed to beat the odds and 
not have the ARVC gene, another type of heart 
disease showed up. 
8. I grew tired of how certain family members 
tried to hide the family history of ARVC from 
the children. 
 
 
            
 
      
           0     1     2     3     4 
 
           0     1     2     3     4 
 
         
           0     1     2     3     4 
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A2. We want to know how much you were thinking about a genetic link (ARVC 
gene) to early sudden cardiac deaths in your family prior to and following 
contact by a geneticist/genetic counsellor. 
 
Using the scale given, you are asked to rate how well each statement reflects 
your situation. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. Over the years concerns were expressed by 
some relatives that there was an ARVC gene in 
our family. 
2. It was only after a geneticist contacted the 
family that I really began to think that the early 
sudden cardiac deaths might be a family thing 
and I could be at risk. 
3. When I was told there was a test that could find 
the ARVC gene in the family, it was not a matter 
of “would I go for genetic testing”, but “when I 
could have it”. 
4. I really questioned whether knowing if I had 
the ARVC gene would do me more harm than 
good (i.e., restricted insurance coverage and job 
prospects). 
5. Getting heart related testing (e.g., ECG, Holter 
monitor) was such a pain that I did not want to 
do it unless I needed it. 
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           0     1     2     3     4 
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A3. Going through genetic testing may not be the same for everyone. We 
want to know how informed and emotionally prepared you were for this 
experience. 
 
Using the scale given, you are asked to rate each statement in terms of its 
importance in helping you and others decide to take part in genetic 
testing. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
It is important to: 
1. Get enough information in a timely manner 
from geneticists/genetic counselors. 
2. Receive enough information from 
geneticists/genetic counselors about the 
genetic testing process. 
3. Feel no pressure to have genetic testing 
done. 
4. Know if one has the ARVC gene. 
5. Understand one’s risk for hereditary early 
sudden cardiac death and accept the need for 
genetic testing. 
6. Know if one has the ARVC gene to help 
children/grandchildren. 
7. Receive support from geneticists/genetic 
counselors during the genetic testing process. 
8. Feel support and encouragement from 
family and/or friends to take part in genetic 
testing. 
 
            
           0     1     2     3     4 
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A4. There are individuals within every family who struggle with the idea of 
being tested for an early sudden cardiac death gene. When close relatives 
refuse genetic testing, concerns are expressed not only for their future 
well-being but also for their children. 
 
Using the scale given, you are asked to rate how well each statement 
describes your thoughts about family members who refuse genetic testing. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. It is important for all family members at risk 
for early sudden cardiac death to take part in 
genetic testing. 
2. I am really concerned about family members 
who refuse to go for genetic testing. 
3. I feel that family members who refuse to go 
for genetic testing do not understand their 
risks. 
4. I believe that family members who refuse 
genetic testing are fearful of knowing their 
results. 
5. I feel obligated to encourage family members 
who refuse genetic testing to rethink their 
decision.  
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A5. Different thoughts and emotions are experienced by individuals within and 
across families as they wait for the results of genetic testing. 
 
Using the scale given, please rate how well each statement describes your 
feelings about the wait time between the giving of blood for genetic testing and 
the actual receipt of your results. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. It was a very trying time thinking about if I 
could carry a gene for early sudden cardiac death . 
2. I was not really prepared for such a long time 
between having the test done and getting the 
results. 
3. I was unsure about how I would receive my 
results (e.g., phone, letter, in person). 
4. I spent a lot of time thinking about how I would 
react to finding out my genetic testing results. 
5. I wondered if I would understand what my 
genetic testing results really meant for me. 
 
             0     1     2     3     4 
 
 
             0     1     2     3     4 
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A6. People report different support needs during and following receipt of 
their genetic testing results. We are interested in knowing what you felt 
was helpful at the time. 
 
Using the scale given, you are asked to rate the following statements in 
terms of their importance for you. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
It is important to: 
1. Have a family member and/or friend present. 
2. Get a phone call from geneticist/genetic 
counsellor prior to receiving your results. 
3. Have face-to-face contact with a 
geneticist/genetic counsellor when receiving 
your results. 
4. Receive a letter explaining what it means to 
be a carrier/non-carrier for yourself and 
others. 
           
          0     1     2     3     4 
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A7. People react differently to receiving their genetic testing results no 
matter how prepared they think they are. We are interested in knowing 
about your reactions and expectations. 
 
Using the scale given, you are asked to rate these statements in terms of 
how well they reflect your situation after getting your results. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. I felt fully prepared to receive my genetic 
testing results. 
2. I was surprised by my genetic testing results. 
3. Knowing whether or not I had the ARVC gene 
for early sudden cardiac death brought a sense 
of closure to everything. 
4. The information received from the 
geneticist/genetic counsellor about my risk for 
early sudden cardiac death risk was very clear 
and useful. 
5. Follow-up contact with the geneticist/ 
genetic counsellor to discuss healthy lifestyles 
and recommendations about ongoing cardiac 
monitoring would have been helpful. 
6. Overall, it was better to know whether or not 
I had the ARVC gene. 
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A8. We want to know if being a carrier/non-carrier of an ARVC gene 
changes how a person values healthy living and monitoring for reducing 
the risk of sudden cardiac death. 
 
Using the scale given, you are asked to rate the following statements in 
terms of how closely they reflect your beliefs. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. Regular clinical monitoring (e.g., ECG, Holter 
monitor, echocardiography) will help detect 
cardiac problems that show I have this disease 
at an early stage. 
2. Appropriate monitoring is important for 
timely detection of cardiac problems. 
3. Early detection of cardiac problems will help 
improve treatment and disease management. 
4. Healthy living (exercise, diet) and a positive 
attitude will help increase well-being and 
decrease stress. 
5. Taking responsibility for healthy living and 
regular monitoring is important. 
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A9. The presence of early sudden cardiac deaths in the family is often 
important in helping understand personal risk. We are interested in how 
awareness of early sudden cardiac death trends within the family influence 
beliefs and who might be at greater risk for cardiac events. 
 
Using the scale given, you are asked to rate how well these statements reflect 
what you perceive to be happening in your family. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. Family members seem to be affected at a 
younger age. 
2. Men and women seem to be affected 
differently. 
3. Different types of heart disease seem to be 
showing up today more than in past 
generations  
4. The number of family members affected 
seems to be greater with each generation. 
5. Some family members who get the ARVC 
gene seem to be better able to fight the disease 
than others.  
 
             0     1     2     3     4 
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A10.  Not everyone is open to receive information about early sudden 
cardiac death or understand what this could mean for them. We are 
interested in knowing whether family members openly communicate about 
and have a good understanding of their risk. We are also interested in 
difficulties, if any, in telling others about the ARVC gene in the family. 
 
Using the scale given, you are asked to rate how well these statements apply 
to your situation.  
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. In our family, we struggle with knowing 
when to tell young family members about early 
sudden cardiac death. 
2. It is difficult having to tell younger family 
members about their possible risk for early 
sudden cardiac death. 
3. Younger family members seem to be open to 
information about the ARVC gene for early 
sudden cardiac death in the family. 
4. Younger family members seem to 
understand what an ARVC gene in the family 
could mean for them. 
5. It is important for all family members to be 
told about the ARVC gene. 
6. It is hard telling family members about their 
possible risk for early sudden cardiac death. 
7. Family members seem to be open to 
information about the ARVC gene. 
8. Family members seem to understand what 
the ARVC gene could mean for them. 
9. It would be helpful if the family messenger 
had guidance and support from geneticists/ 
genetic counselors on how to tell others about 
the ARVC gene. 
10. It is important to protect the rights of 
others when talking about the risk of early 
sudden cardiac death in the family. 
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           0     1     2     3     4 
 
           0     1     2     3     4 
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11. I feel comfortable telling family members 
about the ARVC gene in the family and the 
availability of genetic testing.  
12. I find it difficult telling family members who 
I have limited contact with about the ARVC 
gene and the availability of genetic testing. 
 
 
            0     1     2     3     4 
 
 
            0     1     2     3     4 
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APPENDIX D 
Psychosocial Adjustment to Hereditary Disease Survey 
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Psychosocial Adjustment to Hereditary Diseases (PAHD) Scale 
(ARVC Version) 
 
  
 
The PAHD Scale has 2 sections with a total of 19 questions. 
 
Each question has several statements that we would like you to rate 
from 0 (Not at all) to 4 (Extremely). 
 
Please circle the best answer for each. 
 
Thank you 
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B1: We are interested in the long-term effects of a confirmed ARVC gene for 
early sudden cardiac death in families. Everyone goes through periods of 
trying to make sense of inner feelings about what the future might hold for 
the self and other family members. 
 
Using the scale given, you are asked to rate how well each statement reflects 
your situation. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. I think about being a carrier/non-carrier 
more than I should. 
2. I try to be positive about my future health 
and overall well-being. 
3. It is important for my future health not to 
dwell on the hereditary link to early sudden 
cardiac death in the family. 
4. It was hard changing how often I had to be 
monitored for cardiac disease.  
5. It bothers me when others do not accept my 
carrier/non-carrier status. 
6. Younger people need to be encouraged to 
talk about all the early sudden cardiac deaths in 
the family. 
7. I find it hard dealing with younger family 
members who get the ARVC gene. 
8. I worry about what the future might hold for 
younger family members. 
9. The stress of so much early sudden cardiac 
death in the family, more so in younger 
members, pulled some of us closer together but 
pushed others apart. 
10. Regular monitoring for cardiac problems 
became a constant reminder of my risk by 
being in this family. 
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B2: Some families handle the challenges of an early sudden cardiac death 
(ARVC) gene presence better than others do. We want to know how well 
individuals in your family support one another. 
 
Using the scale given, you are asked to rate how well each statement 
reflects your situation. 
 
0 – Not at all 
1 – A little bit 
2 – Moderately 
3 – Quite a bit 
4 – Extremely 
 
 
1. Feeling supported by family and friends has 
helped me accept being a carrier/non-carrier. 
2. I find it easy to seek help from family 
members when I need it. 
3. It is important for everyone to talk openly 
about the high early sudden cardiac death risk 
in the family. 
4. I am concerned that the presence of early 
sudden cardiac death has hurt family relations. 
5. I worry that all the suffering and death from 
ARVC is placing too much burden on family 
members. 
6. Providing care to other family members with 
ARVC has helped me become more accepting of 
my future. 
7. With so much early sudden cardiac death in 
the family I worried that something would 
show up on my next screening test. 
8. When I knew there was a test to see if my 
family had the ARVC gene for early sudden 
cardiac death, I was relieved. 
9. Encouragement and support from family and 
friends helps one accept the need for healthy 
living.  
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Please tell us anything else you think is important for you or your family in 
living with ARVC. 
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